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ABSTRACT 
              While natural peptides, are ideal starting points for peptide-based drug design and development, 
they suffer from high conformational instability, which results in susceptibility to proteolytic degradation 
and poor bioavailability. Peptidomimetics in recent years has helped circumvent these shortcomings by 
improving the pharmacological properties of polypeptides. Peptidomimetics contain essential elements 
(pharmacophores) that mimic a natural peptide or protein in 3D space and retain the ability to interact 
with the biological target producing the same biological effect. In contrast, they offer conformationally 
restricted structures, potentially minimizing cross-target interactions, which leads to better transport 
properties through biologic membranes and resistance to immune responses.  
              Over the years, a wide variety of side chain modified polypeptides have been developed. These 
modifications have been found to affect both functional as well as conformational properties of 
polypeptides. This important application has proven to be the motivating force behind the two research 
projects described in this thesis.  
            The site selective cleavage of peptide bonds is an essential complementary tool in protein 
sequencing and various bioanalytical and biotherapeutic applications of peptides and proteins.  In order 
to cleave unreactive peptide bonds, mild and metal free, a glutamic acid selective cleavage methodology 
with a broad substrate scope has been developed as reported in Chapter 2 of this thesis. This methodology 
involves activation of side-chain carboxylate groups of glutamic acid residues followed by nucleophilic 
attack of the backbone amide nitrogen resulting in the formation of a cyclic pyroglutamate imide 
intermediate. The latter renders the scissile peptide bond susceptible to cleavage under neutral aqueous 
conditions. Most importantly, the strategy provides an efficient tool for peptidolysis in a wide range of 
peptide sequences, including Pro-Glu, disulfide bonding sites and at unnatural amino acid residues such 
as D-amino acids in mutated peptides. The latter provides a chemical tool for cleaving peptidomimetics 
 vi 
that are unsuitable substrates for proteases and may be potentially applicable for determining the 
mutations responsible for various age-related disorders.  
           Though conformational instability of peptides resulting in reduced bioavailability limits their use as 
promising drugs, constraining peptides by stapling (or cyclizing the side chain components in peptides) 
improves their pharmacological performance by imparting structural stability and increased 
bioavailability. In this regard, a biocompatible, mild and metal free stapling methodology with a broad 
substrate scope is reported in Chapter 3 of this thesis. In this method, the nucleophilic side chain of lysine 
is modified by reaction with an electrophilic bifunctional carbonylating agent to form urea stapled 
peptides with increased α-helicity and improved proteolytic stability. Additionally, the stapling strategy 
demonstrated the ability to synthesize bicyclic peptides with potential applications in peptide-based drug 
design. Most importantly, the urea moiety is anticipated to form strong H-bonds, which may be useful in 
catalyzing organic asymmetric transformations.   
           In summary, the research reported in this thesis describes design, development of peptidomimetics 
through side-chain modifications of glutamic acid and lysine residues and their significant potential 
applications in peptide based synthetic chemistry and drug design. 
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CHAPTER 1: GENERAL OVERVIEW OF PEPTIDE AND PEPTIDOMIMETIC BIOCHEMISTRY, METHODS FOR 
CHEMICAL SYNTHESIS, CHARACTERIZATION AND APPLICATIONS 
 1.1 INTRODUCTION TO AMINO ACID AND PEPTIDE STRUCTURE 
           Amino acids are critical to life as they are the building blocks of peptides and proteins.1 The twenty 
naturally occurring amino acids that are found within proteins contain versatile chemical structures and 
function in biological systems.2 In terms of its structure, each amino acid contains a central carbon atom, 
called the α-carbon, to which both a basic amino and an acidic carboxylic acid group is bound. A hydrogen 
atom and R group chemically bound to the central α-carbon satisfy the remaining tetravalent bonding 
arrangement for the tetrahedral amino acid structure (Figure 1.1). At physiological pH (about 7–7.4), 
amino acids exist largely as dipolar ions or zwitterions effectively making them neutral in the absence of 
a charged side chain group (Figure 1.1).3 As the carbons of standard amino acids, except glycine, are 
attached to four different groups, they exist as two enantiomers, D(R) and L(S). Though only L-amino acids 
are common, mutations, chemical and enzymatic modifications can give rise to some D-amino acids.4 
   
Figure 1.1 General amino acid structure. 
           Distinguishing the naturally occurring amino acids is the composition of the side chain R group, 
which gives each amino acid its unique chemical, structural and biophysical properties. Based on the 
  2 
nature of the R group, amino acids can be classified into the following four categories: hydrophobic 
(nonpolar side chains), polar (uncharged residues with hydrophilic character), acidic (side chains with a 
negatively charged carboxylate groups), and basic (side chains with a positively charged nitrogen) (Figure 
1.2).2  
 
Figure 1.2. Venn diagram of amino acid properties. 
(https://commons.wikimedia.org/wiki/File:Amino_Acids_Venn_Diagram.png) 
Amino acids are joined by an amide or peptide bond to form peptides through condensation 
reactions. In this reaction, an amino group of one amino acid reacts with the carboxylic acid group 
of the other amino acid to form the peptide bond with the concomitant elimination of a water 
molecule (Scheme 1.1).1  Peptides are formed with shorter (<50) amino acid sequences, whereas 
peptides >50 amino acids are classified as proteins. The different amino acids in a peptide and the 
order in which they are found from the N->C terminus is referred to as the primary peptide 
structure.5 
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Scheme 1.1 Peptide bond formation.  
  Peptides have their unique structural and biochemical characteristics, such as an isoelectric pH 
(pI) and ionization behavior depending on the quantity and type of each amino acid within the peptide 
sequence.  For example, the acid-base behavior of a peptide is defined by the zwitterionic nature of the 
amino acid residues within the chain as well as the ionic structure of the N and C-terminal groups. All 
these characteristics influences peptide structure and function in a biological system.  
1.2 IMPORTANCE OF PEPTIDES IN BIOLOGY 
Some 7,000 naturally-occurring peptides are present in all organisms with size varying from two 
to twenty amino acid residues, with biological and physiological functions that impacts bodily functions 
and human health.6,7  Some noteworthy examples (Figure 1.3) include Carnosine, an antiglycating 
dipeptide found in muscle tissue promoting longevity and general well-being (1.1),8 Melanostatin, a 
tripeptide hormone that inhibits the release of melanocyte-stimulating hormone (1.2),9 Cholecystokinin, 
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a tetrapeptide hormone acting primarily in the brain as an anxiolytic (1.3),8  and Oxytocin, a nonapeptide  
which plays a role in social bonding, childbirth and milk production (1.4).8 Peptides like Somatostatin and 
Vasopressin have important roles in  physiological functions.8 The tetradecapeptide Somatostatin  not 
only  controls the production of several hormones such as the growth hormones, thyroid stimulating 
hormones, insulin, glucagon and gastrointestinal hormones, but also regulates the rapid reproduction of 
normal and tumor cells and acts as a neurotransmitter in the nervous system (1.5).8    Similarly, the 
nonapeptide Vasopressin, an antidiuretic hormone helps water retention in the body for proper cellular 
function and maintains proper flow of urine from the kidneys (1.6).8  Thus,  peptides have evolved to 
exhibit diverse biological roles, most prominently as signaling/regulatory molecules in a broad variety of 
physiological processes, including defense, immunity, stress, growth, homeostasis, and reproduction.10 
Their diverse biological functions has enabled the development of medicinal chemistry programs to 
improve their therapeutic potential towards a variety of diseases and disorders. 
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Figure 1.3  
Bioactive peptides found in nature 
1.3 PEPTIDE SYNTHESIS OVERVIEW 
Peptide synthesis has enabled the production of many natural peptides such as hormones, 
neuropeptides and antibiotics, which are otherwise difficult to isolate from nature in sufficient quantities 
for their therapeutic applications. The first peptide synthesis of glycylglycine (Gly-Gly), as well as the term 
“peptide,” was first reported by Fischer and Fourneau in 1901 (Scheme 1.2).11, 12  In this method, 2,5-
  6 
diketopiperzaine was effectively hydrolyzed to Gly-Gly using acid catalyzed conditions. These harsh 
conditions are not applicable to other peptides containing functional side chain groups and lengthier 
sequences.               
 
Scheme 1.2 The first synthesis of a dipeptide by E. Fischer12 
  In order to overcome the synthetic challenges associated with peptide synthesis, a removable 
amino-protecting group was developed by M. Bergmann and L. Zervas by use of the carbobenzoxy (Cbz) 
group.  
In addition to the transient protecting group strategies, carbodiimide-based coupling strategies 
developed in 1955 by J. C. Sheehan, G. P. Hess14 and H. G. Khorana15 gave the ability to form peptide bonds 
more rapidly and efficiently. Therefore, the combination of blocking/deblocking the N-terminus followed 
by activation and coupling of C-terminal amino acids enabled the production of a solution phase synthesis 
approach (Scheme 1.3).13-15  This resulted in synthesis of an active hormone, the octapeptide Oxytocin 
(Figure 1.3, peptide 1.4) leading to  a new era of peptide synthesis, for which du Vigneaud  was later 
awarded the Nobel Prize.13 
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Scheme 1.3. Solution-phase peptide synthesis of Oxytocin 
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1.3.1 SOLID PHASE PEPTIDE SYNTHESIS 
The most conspicuous breakthrough discovery in the field of peptide synthesis was the invention 
of solid phase peptide synthesis (SPPS) by R. B. Merrifield in 1963.16  An insoluble, polystyrene-based solid 
support was utilized for the synthesis of peptide sequences. After extensive research, Merrifield 
determined the best conditions for the solid phase synthesis, which ultimately led to the Nobel Prize in 
1984 (Scheme 1.4).  
 
Scheme 1.4 SPPS procedure followed by Merrifield.  
SPPS was later modified to use the t-butyloxycarbonyl (Boc) group for Nα-protection17 which is 
labile in the presence of trifluoroacetic acid, (TFA), and hydrogen fluoride (HF) as the reagent for removal 
of the peptide from the resin.18 The Nα-protecting group, Boc is labile in the presence of TFA while side-
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chain-protecting benzyl (Bn)-based groups and the peptide/resin linkage were stable in the presence of 
moderate acid and labile in the presence of strong acid (HF) ( Scheme 1.5). 
 
Scheme 1.5 General solid phase peptide synthesis protocol 
In 1970, Carpino introduced the 9-fluorenylmethoxycarbonyl (Fmoc) group for Nα protection,19 
which is removed using a mild base, piperidine. This Fmoc-SPPS strategy also utilized TFA-labile t-butyl 
(tBu)-based side-chain protection and hydroxymethylphenoxy-based linkers for peptide attachment to 
the resin, making it an “orthogonal” synthesis (Scheme 1.5). The milder conditions of Fmoc chemistry, 
along with improvements in basic peptide chemistry, have led to a shift in making peptides from solution-
phase to solid-phase methods. 
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Solid-phase synthesis has many advantages over the classical solution-phase method, although 
there are a few drawbacks associated with peptide purification following cleavage and deprotection from 
the solid support and the concomitant cleavage of byproducts accumulated during synthesis.20  Desirably, 
the solid-phase synthesis method can be automated and the problem of solubilization of the peptide no 
longer exists since it remains attached to the solid matrix.  With significant advances in the development 
of polymeric carriers and linkers, reversible protective groups21 and methods for the activation of peptide 
bond formation,2 SPPS has contributed as a powerful tool for advancement of protein and peptide 
research. 
1.3.2 PROTECTING GROUP STRATEGIES  
In the last few years,  more than 250 protecting groups have been found suitable for peptide 
synthesis.23 Two main protecting groups strategies have been adopted for SPPS, the t-Boc/Bzl and 
Fmoc/tBu strategies24. In t-Boc/Bzl, the t-Boc (tert-butoxycarbonyl) group is used for the protection of the 
Nα amino group and a benzyl or cyclohexyl for the side chains of several amino acids. In Fmoc/tBu, the 
Fmoc (9-fluorenyl methoxycarbonyl) group is used for the protection of the Nα amino group and the tert-
butyl group for the side chains of different amino acids in the peptide (Scheme 1.5 and  Table 1.1).25 
Table 1.1 Commonly used protecting groups for the side chains in t-Boc/Bzl and Fmoc/t-Bu trategies.26 
Amino acid Side chain group 
Protecting group 
Fmoc strategy t-Boc strategy 
serine R-OH t-butyl benzyl (Bzl) 
threonine R-OH t-butyl  benzyl (Bzl) 
tyrosine Ph-OH t-butyl 2-Br-benzyloxycarbonyl 
cysteine R-SH trityl p-methylbenzyl 
aspartic acid R-COOH t-butyl benzyl 
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glutamic acid R-COOH t-butyl benzyl 
lysine R-NH2 t-butyloxycarbonyl 2-Cl-benzyloxycarbonyl 
arginine R-NH-C(=NH)-NH2 2,2,5,7,8-pentamethyl- 
croman-6-sulfonyl 
tosyl 
histidine 
 
 
trityl tosyl 
2.4-dinitrophenyl 
tryptophan 
 
 
t-butyloxycarbonyl formyl 
 
1.3.3 SOLID SUPPORTS  
Solid supports for SPPS have to meet several requirements. Notably, the resin should be of 
conventional and uniform size, mechanically robust, easily filterable, chemically inert, stable under the 
conditions of synthesis and highly accessible to the solvents, which should allow the penetration of the 
reagents and the lengthening of the peptide chain. They must not interact physically with the peptide 
being synthesized and should be capable of being functionalized by a starting amino acid residue.  
Many solid supports for SPPS include composite polymer materials and functionalized surfaces. 
As homogeneous gel resins, such as those belonging to poly(ethylene) glycol (PEG) have shown optimal 
performance during solid-phase peptide synthesis. Their loading, physical and chemical properties can be 
varied easily, making these mechanically stable, beaded, homogeneous gel resins preferred for SPPS.27,28 
Also, optimal properties have been obtained by radical polymerization of end group acryloylated long-
chain PEG.29 However, as the reactivity of radicals, carbenes, carbanions, carbenium ions, or strong Lewis 
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acids have to be considered for general organic synthesis, polystyrene resins have been found to be more 
suited (Figure 1.4).29 
Two types of polystyrene resins- uncrosslinked and crosslinked are available, where uncrosslinked 
resins dissolve in hydrophobic solvents. Moreover, they precipitate in protic solvents. So polystyrene 
supports used in solid phase chemistry contain 1% or 2% divinylbenzene (DVB) as a crosslinking agent and 
are insoluble in all common organic solvents.  Typically, these resins are utilized as small, spherical beads 
and are functionalized with reactive linker groups such as amine or hydroxyl groups, on which peptide 
chains can be built.30 The peptide remains covalently attached to the support throughout the synthesis. 
 
Figure 1.4 Solid support for peptide synthesis. 
  Polystyrene beads are available in sizes ranging from less than a micron to 750 microns in 
diameter.  Reaction kinetics are faster on smaller beads due to the higher surface area to volume 
ratio.  Beads in the range of 75 to 150 microns in diameter offer a good balance of reaction kinetics versus 
reliability.  Bead size is reported in Tyler Mesh size. Two commonly used resin sizes are 100-200 mesh and 
200-400 mesh. 31 
Many polymeric supports are now available and can be derivatized with functional groups to 
produce highly stable linkages 32 and peptides with different functionalities at the terminal carboxyl group 
including amide, acid and thioester groups.33 Some examples are the p-methoxybenzhydrylamine 
(MBHA), 4-hydroxymethyl-phenylacetamidomethyl (PAM) and hydroxymethyl functionalized resins used 
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for t-Boc/Bzl and 4-(2',4’-dimethoxyphenyl-aminomethyl)-phenoxymethyl-polystyrene (Rink), 2-
chlorotrityl chloride, and diphenyldiazomethane functionalized resins used for Fmoc/t-Bu (Figure 1.5). 
 
Figure 1.5 Functionalized resins for t-Boc/Bzl and Fmoc/t-Bu SPPS 
 
1.3.4 COUPLING REAGENTS 
Amide bond formation is initiated by nucleophilic attack of the N-terminus amino group of an 
amino acid on the electrophilic, activated carboxyl group of the neighboring amino acid (Scheme 1.5). 
Coupling reagents such as the carbodiimides, dicyclohexylcarbodiimide (DCC) and 
diisopropylcarbodiimide (DIC) have been frequently  used as 'activators' to lower the activation energy 
barrier associated with amide bond forming reactions (Figure 1.6). 
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Figure 1.6 Peptide coupling reagents 
Considering carbodiimide-based coupling conditions can lead to racemization and epimerization, 
additives such as 1-Hydroxybenzotriazole  (HOBt) and 1-Hydroxyazabenzotriazole (HOAt) have been also 
added to the reaction mixture to  minimize epimerization via the formation of a more reactive 'active 
ester' species in situ (Scheme 1.6).36 Towards this effect, more reactive coupling reagents such as the 
phosphonium and uronium based reagents have been more commonly used in SPPS with minimal effects 
on peptide racemization and epimerization.  
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Scheme 1.6 Amide bond formation using DIC/HOBt 
1.3.5 PEPTIDE CLEAVAGE FROM SOLID SUPPORT   
Following SPPS, the crude peptide is cleaved from the solid support while the protecting groups 
are also removed using strong acids such as trifluoroacetic acid or a nucleophile, such as reactive thiols or 
amines.37 The crude peptide is subsequently precipitated in diethyl ether to remove organic soluble 
impurities and purified by reverse-phase (RP) HPLC.38 
1.4 PEPTIDOMIMETICS 
In spite of their biological activity, native peptides are prone to proteolytic degradation, limited 
cell permeability, non-specific and low affinity binding to receptor targets which impedes their duration 
of action. 39, 40  These drawbacks limit their use as drugs.41 These limitations can be circumvented by 
modifying the peptides to improve their pharmacokinetic properties, which forms the basis for the field 
of peptidomimetics.42 
Peptidomimetics are synthetic or biological molecules whose essential elements 
(pharmacophores) mimic a natural peptide in 3D space and retain the ability to interact with the biological 
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target and produce the same biological effect as the native peptide.42 In the rational design of 
peptidomimetics, different important factors such as binding site optimal fit, polar or hydrophobic regions 
and conformational stabilization43 must be considered. These structure-activity relationships (SAR) define 
a minimal active sequence or major pharmacophore elements responsible for the biological effect. The 3-
D arrangement of the binding site key residues are used to re-assemble these critical elements on a 
modified scaffold.42 
           Several different strategies including the cleavage of endogenous precursor peptides,44,45 L to D 
amino acid substitution,46 unnatural amino acids substitution46 or cyclization involving side chains have 
been explored in peptidomimetcs (Figure 1.7). 
 
Figure 1.7 Peptidomimetics: different methodologies 
Different synthetic methodologies for making cyclic peptidomimetics include side chain-to-side 
chain, head-to-side chain, side chain-to-tail cyclization and backbone cyclization,4747 peptide stapling,48 
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and native chemical ligation.49 Cyclic peptidomimetics are widely used in the clinic, where chemically 
stable bonds, such as amide, lactone, ether, thioether, or disulfide bonds are used to confer a stable 
peptide backbone for improved therapeutic effects in biological systems (Figure 1.8).  
B  
Figure 1.8 Amino acid side chain modifications.  
1.5 THESIS OBJECTIVES 
Over the years, a wide variety of side chain modified polypeptides have been developed to affect 
both conformational as well as functional properties.50 In this thesis, the effect of cyclic conformational 
constraint on the peptide backbone and side chain geometry are explored as chemical tools for improving 
peptide SARs against biological targets.  
For example, Chapter 2 of this thesis describes the activation of the side-chain carboxylate group 
in Glutamic acid (Glu) to form a cyclic backbone intermediate, pyroglutamate, pGlu imide moiety by 
nucleophilic attack of the amide nitrogen, making the C−N bond prone to hydrolysis (Scheme 1.7). Taking 
advantage of the susceptibility of pGlu imide moiety towards hydrolysis, we developed a new mild and 
metal-free methodology which cleaves the unreactive peptide bonds specifically at Glu in native as well 
as in mutated peptides, containing amide bonds unsuitable for enzymatic degradation. 
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Scheme 1.7. Cyclization and cleavage of peptide bonds by formation of reactive pGlu imide intermediate 
Cyclized peptides have many advantages such as increased cell permeability,6 resistance towards 
proteolytic degradation, enhanced bioactivity and enhanced binding to target molecules.7 Chapter 3 of 
this thesis describes a new methodology for making cyclic peptides by virtue of a urea based methodology 
for stapling the cyclic peptide (Scheme 1.8). In this methodology, the Lysine (Lys) ε-amine group is 
intrinsically nucleophilic51 with pKa values of 10.4 in model compounds.52 Amino-acid nucleophiles have 
been reacted with electrophilic groups to create drugs.51 In this application, the nucleophilic ε-amine 
group of the Lys side chain is modified by a carbonyl donor to activate the peptide side chain for cyclization 
reaction. 53, 54, 55 
 
Scheme 1.8. Synthesis of urea-bridged peptides 
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In this manner, a carbonylating agent behaves as an electrophilic bifunctional linker providing 
structural rigidity and conformational preorganization to the peptide scaffold. This method provides a 
new mild, metal-free stapling strategy to build cyclic peptides with improved pharmacological properties 
such as increased proteolytic stability and alpha helicity. Moreover, we have adapted the methodology to 
build bicyclic compounds, as bicyclic compounds are capable of creation of a new generation of 
biotherapeutics (Figure 1.9 b).5631 
 
Figure 1.9. Structures of cyclic and bicylic compound synthesized in this study (R may be same or 
different) 
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CHAPTER 2:  PYROGLUTAMATE - A CYCLIC BACKBONE INTERMEDIATE FOR SELECTIVE CHEMICAL 
CLEAVAGE OF PEPTIDE BONDS 
2.1 ABSTRACT 
              Cleavage of peptide bonds at a specific residue is an indispensable biochemical tool to explore 
various biotechnological, bioanalytical and bioengineering applications of peptides and proteins. 
Proteases, which hydrolyze peptide bonds at specific amino acid residues, have proven to be of a great 
importance in chemical biology applications. However, their inability to recognize and cleave modified 
peptides or peptidomimetics limits their potential. Many emerging applications which involve 
peptidomimetics necessitate the need for new chemical reagents with improved efficiency for the 
cleavage of peptide bonds. These chemical reagents must selectively recognize and bind to one or more 
amino acid residues in the peptide sequence and specifically cleave the peptide bond at the reaction site. 
Based on this principle, we have developed a methodology, in which bromotris (pyrrolidino)phosphonium 
hexafluorophosphate (PyBrOP) is used to modify the side-chain carboxylate of glutamic acid, rendering  it 
prone to hydrolysis. In this reaction, activation with PyBrOP produced a reactive pyroglutamate imide 
intermediate which upon incubation in buffer led to cleavage of the scissile peptide bond at the N-
terminus of the modified glutamic acid residue. The strategy presents a valuable complementary tool for 
peptide and protein sequencing with a broad substrate scope, including cleavage of bioactive peptides 
and mutated peptides with unnatural D-amino acid residues implicated in various diseases. 
2.2 CHAPTER OBJECTIVES 
            In this chapter, the development of an artificial chemical protease for the site-selective cleavage of 
unreactive peptide bonds at glutamic acid is described. The site selective cleavage of a peptide bond is an 
essential complementary tool in peptide and protein sequencing as well as to explore various applications 
of peptides and proteins in chemical biology.1 The amide bonds, however, are extremely unreactive 
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towards hydrolysis with a half-life of 500-1000 years at room temperature and pH 4-8.2 The extreme 
stability of peptide bonds limits the range of appropriate peptidolysis reagents.3  Though different 
proteases,4 metals,5 self-cleaving intein sequences, 1 and various chemical reagents 6, 7, 8 like cyanogen 
bromide are used for proteolysis, they suffer from inherent drawbacks such as the requirement for 
specific temperature and pH ranges, extended cleavage reaction times, toxic metals and harsh chemical 
conditons9 that are ill-suited for the cleavage of amide bonds, particularly in modified peptides. In order 
to address these limitations, a mild, metal-free methodology for cleaving amide bonds in native peptides 
as well as peptidomimetics is described in Chapter 2 of this thesis. This methodology involves selective 
modification of the side-chain carboxylic acid group of a Glutamic acid (Glu) residue, followed by cleavage 
specifically at the modified scissile bond under neutral aqueous buffer conditions. Furthermore, this 
chapter highlights the rational design, method development and substrate scope for this newly applied 
peptide cleavage strategy. This methodology provides an effective tool for peptidolysis specifically at the 
Pro-Glu peptide bond found within native sequences and mutated peptides which contained unnatural 
D-amino acids that are typically non-substrates for digestive enzymes. Thus, this methodology has 
extended the scope of chemical methods used for cleaving peptide bonds while providing significant 
insights into the development of a synthetic self-cleaving peptidase. Respectively, these findings may lead 
to important contributions to the field of peptide sequencing as well as in the design of new chemical 
systems that can mimic enzyme activity.   
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2.3 GRAPHICAL ABSTRACT 
 
              Site-specific hydrolysis of peptide bonds at glutamic acid under neutral aqueous conditions is 
reported. The method relies on the activation of the backbone amide chain at glutamic acid by the 
formation of a pyroglutamyl (pGlu) imide moiety. This activation increases the susceptibility of a peptide 
bond toward hydrolysis. The method is highly specific and demonstrates broad substrate scope including 
cleavage of various bioactive peptides with unnatural amino acid residues, which are unsuitable 
substrates for enzymatic hydrolysis. 
 
This article was first published on February 11, 2016. 
Figure 2.1 Graphical abstract for Glutamic Acid Selective Chemical Cleavage of Peptide Bonds. 
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2.4 INTRODUCTION 
               Site-selective cleavage of peptide bonds is a valuable source of insight into human proteomics as 
well as to explore various biotechnological, bioanalytical and bioengineering applications of peptides and 
proteins.1 
                Conventionally, peptidases are used quite prevalently for residue-selective hydrolysis of peptide 
bonds,4 such as trypsin, which is selective for cleavage at the basic of Arg and Lys residues, chymotrypsin 
and pepsin which are  selective for cleavage at aromatic hydrophobic amino acids, Phe, Trp, and Tyr 
(Figure 2.2). While proteolytic enzymes cleave proteins with great accuracy, efficiency and specificity, they 
suffer from many disadvantages. They need high specificity at their site of action, for instance, they will 
attack a peptide bond, provided the appropriate category of amino acid side chain defined  by lipophilicity, 
steric properties etc.,  is present for substrate recognition.11 In addition, they tend to produce short 
fragments that are ill-suited for sequencing and contaminate the protein digest.12  Proteases require 
narrow ranges of pH and temperature. Moreover, organic solvents often destabilize and inactivate 
peptidases.13 
 
Figure 2.2 Peptidase digestion of a polypeptide 
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            To circumvent the limitations faced by biological enzymes, various chemical methods are used for 
controlled cleavage of peptides and proteins. One of the early methods for protein sequencing was N-
terminal amino acid analysis by Frederick Sanger, where he used Fluorodinitrobenzene (FDNB), 14 though 
instead, Dabsyl chloride is more commonly used now, as it forms fluorescent derivatives easy to detect 
with high sensitivity.  Dabsyl chloride reacts with uncharged α-NH2 group to form a stable sulfonamide 
derivative that hydrolyzes peptide bonds (Scheme 2.1) as dabsyl-amino acid, which could be identified by 
its chromatographic properties. 
 
Scheme 2.1 Dabsyl chloride N-terminal amino acid analysis.  
           Though sensitive and powerful, the method degrades the peptide in the acid-hydrolysis step and 
thus all sequence information is lost.15  To overcome this drawback, Edman devised a method for cleaving 
amino-terminal residue from the peptide without disrupting the peptide bonds between the other amino 
acid residues (Scheme 2.2).    
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           Edman degradation is by far the most important and widely used method due to its efficiency, 
sensitivity and simplicity. 16 This method uses phenyl isothiocyanate to cleave the amino acid one by one 
from the amino terminal. Under mildly alkaline conditions, the thiazolinone derivative of uncharged N-
terminal acid is formed, which is converted to more stable phenylthiohydantoin (PTH)-amino acid under 
mildly acidic conditions, cleaved and then identified using chromatographic procedures. 
 
Scheme 2.2 Edman degradation method for protein N-terminal sequencing. 
          Repeated cycles of phenyl isothiocyanate can elucidate the complete sequence of the original 
peptide, though it renders the method exhaustive and time consuming. In addition, as the length of the 
peptide increases, the efficiency of the method deceases. Even peptides less than 50 amino acids in length 
can become problematic in practice.  
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          To complement these methods, some other chemicals such as cyanogen bromide,17 ο-iodosobenzoic 
acid19 are also used to fragment the original protein at specific amino acids into smaller peptides to 
facilitate sequencing. Cyanogen bromide hydrolyzes peptide bonds at the C-terminus of methionine 
residues forming a homoserine lactone, though, when methionine is followed by serine or threonine, side 
reactions can destroy the methionine without peptide bond cleavage, limiting the scope of the method 
(Scheme 2.3).   
 
Scheme 2.3 Cyanogen bromide mediated cleavage of a peptide bond at methionine residue.  
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         Similarly, ο-iodosobenzoic acid cleaves peptide at tryptophan residues, but it also modifies tyrosyl 
residues in the peptide chain (Scheme 2.4).19   
 
Scheme 2.4 ο-iodosobenzoic acid mediated cleavage of a peptide bond at tryptophan residue. 
 
              Different metal complexes with high catalyst turnovers, especially those containing ZnII,CoII, FeIV 
and  CuII have been rationally synthesized for hydrolytic or oxidative cleavage of peptide bonds. For 
example, recently Kanai and Oisaki reported a serine-selective peptide-cleavage strategy that proceeds 
through mild aerobic oxidation promoted by a water-soluble copperII -  organoradical conjugate (Scheme 
2.5).20  Still, practical applications of metals for protein analysis is still in its early stages.21-27  
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Scheme 2.5 CopperII - organoradical conjugate mediated cleavage of a peptide bond at serine residue.  
 
                Site-specific peptide bond cleavage methods have advanced significantly in the last 10 years. 
These have proven to be valuable chemical tools for biologically active peptides and peptidomimetics with 
their ability to hydrolyze mimetics comprised even of unnatural D-amino acids, thereby complementing 
enzymatic methods. However, these methods lag behind natural peptidases in activity, efficiency, 
cleavage site-fidelity, and substrate specificity due to different inherent shortcomings. For rapidly 
developing peptidomimetics, it is essential to bridge this gap with useful and practical artificial peptidases. 
Realizing the need for a rationally designed synthetic chemical cleavage strategy, we envisioned glutamic 
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acid (Glu) as a selective amino acid residue for the chemical cleavage of peptide bonds. The methodology 
entails activation of the side-chain carboxylate of Glu by formation of pyroglutamyl (pGlu) imide moiety 
(B) 28 rendering the imide C–N bond susceptible to hydrolysis which leads to the cleavage of the peptide 
bond (Scheme 2.6). 
2.5 RATIONAL DESIGN OF CYCLIC PYROGLUTAMYL (pGLU) IMIDE MOIETY CONTAINING PEPTIDES 
            In order to construct peptides with a C-N bond susceptible to hydrolysis, we decided to explore an 
approach of cyclizing the side chain carboxylic acid of a Glu residue in the peptide chain. We envisioned 
that Glu would favor formation of the kinetically preferred 5-membered pyroglutamyl (pGlu) imide ring 
following activation and cyclization. We proposed to activate the side chain carboxylic group of Glu into a 
reactive acyl chloride which would facilitate nucleophilic attack by the backbone amide nitrogen atom 
subsequently leading to cyclization (path A, Scheme 2.6). In principle, this cyclization reaction could lead 
to a 5-membered pyroglutamyl (pGlu) imide moiety28 B by path a or 6-membered piperidinedione B’ by 
path b (Scheme 2.6). As the amide nitrogen of glutamic acid would have spatial proximity to its activated 
carboxylic group, we envisioned formation of the kinetically favored 5-membered pGlu imide moiety 
would be favored to render the scissile amide bond susceptible to hydrolysis, subsequently leading to 
desired cleavage at N- terminal of the Glu residue (Scheme 2.6). 
  33 
 
Scheme 2.6 Rationale for the glutamic acid-selective modification and peptide cleavage in neutral 
aqueous solution. 
 
2.6 RESULTS AND DISCUSSION 
          To achieve the generation of the pyroglutamyl imide moiety by cyclization at Glu, various activating 
agents were explored to activate the carboxylic acid side chain of Glu on a model hexapeptide Fmoc-Val-
Ala-Glu-Arg-Phe-Ala-NH2 (1a) (retention time tR = 13.7 min). The peptide was synthesized by Fmoc solid 
phase peptide synthesis (SPPS) with the N-terminal Fmoc protecting group present to avoid side reactions. 
A series of acylating agents for activating Glu were explored (Table 2. 1). The % conversions from 1a to 2a 
were calculated by comparing peak areas of product to starting material from the HPLC data, which was 
further confirmed by molar mass obtained by mass spectrometry. In initial studies with N, N′ 
disuccinimidyl carbonate (DSC), a large excess of reagent and longer reaction times were needed for 50% 
conversion to the desired cyclized peptide 2a (entry 1, Table 2. 1). 
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Table2.1. Acylation reagents screening for formation of pGlu Imide Moiety 2aa 
 
entry reagent (equiv) base (equiv) additive time (h) convd (%) convb (%) 
1 DSC (40) DIEA (40) 
 
48  50 
2 PyBrop (20) DIEA (20) 
 
24 80 20 
3 PyBrop (20) DIEA (20) 
 
48 60 40 
4 PyBrop (40) DIEA (40) 
 
48 40 60 
5c PyBrop (20) DIEA (20) DMAP 24 1 99 
aReaction conditions: peptide (1 equiv) was reacted with DSC/PyBrop (20–40 equiv) and DIEA (20–40 equiv) in DMF at room 
temperature.bConversion to 2a was calculated from the absorbance at 254 nm using HPLC. cA small crystal of DMAP was added 
to the reaction mixture. The entry in bold represents the optimized reaction conditions. DIEA = N, N-diisopropylethylamine, DMAP 
= 4-(N, N-dimethylamino)pyridine. d Conversion to 2a’ was calculated from the absorbance at 254 nm using HPLC. Table Reprinted 
with permission from Nalbone, J.M.; Lahankar, N.; Buissereth, L.; Raj, M. Glutamic Acid Selective Cleavage of Peptide Bonds. Org. 
Lett. 2016, 18 (5), 1186–1189. Copyright 2016, American Chemical Society. 
            When one of the more reactive coupling reagents, bromotris(pyrrolidino)phosphonium 
hexafluorophosphate (PyBrOP) was used for activation, with uncrystallized PyBrop, pyrrolide 2a’ as a side 
product was obtained with a mass 53 Da higher than the starting peptide 1a. (entry 2, Table 2.1). (Figure 
2.3).29 , 30, 31  
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Figure 2.3: Pyrrolide side product formation. 
After screening different reaction conditions, recrystallized PyBrOP (20 equiv.), DIEA (N,N-
diisopropylethylamine) (20 equiv.), and catalytic amount of DMAP (4-(N,N-dimethylamino)pyridine)  in 
dimethylformamide (DMF) (0.5 mL) were selected as the reagents of choice (entry 5, Table2. 1) producing 
nearly quantitative conversion to the desired product 2a. Acylated hexapeptide cyclized at Glu after 17 h, 
with a retention time tR = 13.7 min, as analyzed by mass spectrometry (MS).  
                After optimization of the conditions for cyclization of Glu, NMR characterization was performed 
on the sequence Fmoc-Gly-Glu to confirm the formation of the five-membered cyclic ring rather than the 
six-membered ring. (Figure 2.4 and 2.5).10  Based on predicted chemical shifts values32, If the six-
membered ring had been formed, the methine 13C shift value would be 51.6 ppm (Figure 2.5). 
Confirmation of the five-membered cyclic pGlu ring formation was proven by the observed 13C shift value 
of 55.4 ppm, which was close to predicted 13C NMR chemical shift value of 55.5 ppm (Figure 2.5). The 
1H/15N HSQC data clearly ruled out the 6-membered ring structure due to the presence of the primary 
amide (six-membered ring structure would have two secondary amides) (Figure 2.4). In addition, HSQC, 
HMBC and 1H/1H NOSEY NMR were consistent with this structure (Supporting information Figure A1).   
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.   
Figure 2.4 13C NMR and 1H/15N HSQC NMR for modified Fmoc-Gly-pGlu.  Reprinted with 
permission from Nalbone, J.M.; Lahankar, N.; Buissereth, L.; Raj, M. Glutamic Acid Selective Cleavage of 
Peptide Bonds. Org. Lett. 2016, 18 (5), 1186–1189. Copyright 2016, American Chemical Society 
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Figure 2.5 Comparison of NMR chemical shifts for cyclization of Glu: Five-membered ring versus 
a six-membered ring. 
 
              Following the indication that the experimental NMR data matched the predicted spectra for Fmoc-
Gly-pGlu, the modified peptide with pGlu moiety (2a) was subjected to incubation in phosphate buffer of 
pH 7.5 and the reaction progress was monitored by injecting the sample into an analytical HPLC at regular 
reaction time intervals (Figure 2.6). After 48 hours, the sharp peak at 13.7 min disappeared and two new 
peaks appeared. When analyzed by MS, the peaks at 5.6 and 22.7 min proved to be the expected 
hydrolyzed, cleaved peptide products. More specifically, the N-terminal fragment 3a eluted at 22.7 min, 
while the modified C-terminal fragment 4 eluted at 5.6 min. The successful cleavage reaction provided 
additional, indirect supporting evidence for the formation of the 5-membered pGlu intermediate, as the 
6-membered ring cycle would not be susceptible to peptide bond cleavage.   
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Figure 2.6 HPLC chromatogram of pGlu imide formation using optimized reaction conditions HPLC chromatogram of pGlu imide 
formation using optimized reaction conditions in Table 1, entry 5, at t = 0 h (top), at t = 17 h (middle), after hydrolysis under 0.1 
M phosphate buffer (pH 7.5) at 25 °C, and at t = 48 h (bottom). Insets show the MS corresponding to retention times at 13.4 min 
(1a, top), 13.7 min (2a, middle), 22.7 min (3a, bottom), and 5.6 min (4, bottom Reprinted with permission from Nalbone, J.M.; 
Lahankar, N.; Buissereth, L.; Raj, M. Glutamic Acid Selective Cleavage of Peptide Bonds. Org. Lett. 2016, 18 (5), 1186–1189. 
Copyright 2016, American Chemical Society.             
           After successful application of our Glu selective cleavage method to the model peptide Fmoc-Val-
Ala-Glu-Arg-Phe-Ala-NH2 (1a), we decided to probe the steric effect on the efficiency of cyclization and 
subsequent cleavage reaction by varying the side chain functionality of the amino acid residue preceding 
Glu. Also, we were interested in investigating the selectivity of our cleavage strategy towards other 
residues in the peptide chain with reactive functional groups. Various hexapeptides with the general 
sequence Fmoc-Val-X-Glu-Arg-Phe-Ala-NH2 (1a−j) were synthesized to incorporate several different 
residues at position X (Table 2.2). 
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Table 2.2 Glu-Selective Amide Bond Cleavage of Fmoc-Val-X-Glu-Arg-Phe-Ala-NH2 (1a−j) a 
 
entry substrate X convb(%) 
1 1a Ala 99 
2 1b Gly 99 
3 1c Arg 99 
4 1d Met 80 
5 1e Asn 90 
6 1f His 90 
7 1g Phe 90 
8 1hc Tyr 90 
9 1ic Ile 65 
10 1j Asp 99 
aReaction conditions: peptide (1a–j, 1 equiv) was reacted with PyBrop, DIEA (20 equiv), and a crystal of DMAP in DMF at room 
temperature followed by hydrolysis with 0.1 M phosphate buffer (pH 7.5) at 25 °C for 48 h. bConversion to N-terminal fragment, 
Fmoc-V-X-OH (3a–j), was calculated from the absorbance at 254 nm using HPLC.c Hydrolysis for 5 days. Reprinted with permission 
from Nalbone, J.M.; Lahankar, N.; Buissereth, L.; Raj, M. Glutamic Acid Selective Cleavage of Peptide Bonds. Org. Lett. 2016, 18 
(5), 1186–1189. Copyright 2016, American Chemical Society. 
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        In all cases, after incubation in phosphate buffer, pGlu imide moiety containing C-terminal fragment 
4 was obtained with the HPLC conversions ranging from 65 to 99%. Reactions proceeded smoothly in 48 
h similarly to the reaction of 1a for unprotected peptides with X = Gly (1b), Arg (1c), Met (1d), Asn (1e), 
His (1f), and Phe (1g) (entries 2−7, Table 2.2). In contrast, substrates containing X = Tyr (1h) and Ile (1i) 
with bulky side groups gave the cleaved products in good yields but required longer time (5 days) for 
cleavage (entries 8 and 9, Table 2.2). All the above reactions proceeded cleanly without any by-products, 
unlike some other chemical cleavage methods,17, 19   which result in the over-oxidation of Tyr, Trp, and 
Met containing peptides, indicating our mild method is tolerable of many side chain functional groups.  
               Peptide 1j, along with Glu, contains Asp, which also has free carboxylic group. This peptide under 
the reaction conditions could give the four membered -lactam ring (5) or the five membered imide ring 
(6) by cyclization of Asp with Glu (2j). However, product (5) was not observed due to strain involved in the 
formation of the four membered ring. If product 6 had been formed, under the hydrolysis conditions, ring 
opening would occur rather than cleavage of the peptide bond. Instead, hydrolysis led to the fission of 
the peptide bond at the N-terminus of Glu generating two fragments as previously reported and 
confirmed by HPLC and MS. Based on these results, the reactions conditions were determined to be 
selective for Glu (Figure 2.7). 
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Figure 2.7 Reactivity of Asp vs Glu toward the Backbone Activation for Peptide 1j. 
              The methodology was also applied to the cleavage of long peptides with multiple Glu residues and 
even peptides with unnatural D-amino acids, demonstrating its wide substrate scope. Longer 12-mer and 
13-mer peptides (7 and 8) with two Glu residues at internal positions underwent effortless cleavage at 
both glutamic acids and delivered three fragments in high yield (80−85%) (entries 1 and 2, Table 2.3, and 
Supporting Information). Peptide 9 with unnatural amino acid residues and peptide 10, with a mixture of 
L- and D-amino acids, respectively, were cleaved successfully under the reaction conditions at Glu with 
ease and high yields (entries 3 and 4, Table 2.3). Conversion of natural L-amino acids to unnatural D-amino 
acids is a well-known mutation responsible for various age related disorders such as cataracts and 
Alzheimer’s disease, 33 but enzymes cannot recognize and cleave these modified peptides. Thus, this 
method can be used as a diagnostic tool to determine different types of mutations in proteins and their 
role in the progression of diseases.  
                Furthermore, peptide 11 with an intramolecular disulfide bridge afforded the cleavage product 
at glutamic acid with an intact disulfide bond (entry 5, Table 2.3). Thus, this methodology can be used to 
determine the position of disulfide bonding in a peptide chain, which is in contrast to other chemical 
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reagents.34, 35 Peptide 12, containing a serine residue with a reactive hydroxymethyl group at the side 
chain, remained unreacted under the reaction conditions, and cleavage was observed only at Glu (entry 
6, Table 2.3). This again confirmed the high specificity of this methodology toward Glu.  
Table 2.3. Substrate Scope of Glu-Selective Amide Bond Hydrolysisa 
entry substrate yieldb (%) 
1c Fmoc-Ala-Val-Arg-Glu-Val-Ala-Phe-Glu-Arg-Phe-Gly-Phe-NH2 (7) 80 
2c Fmoc-Arg-Ala-Gly-Ala-Glu-Val-Arg-Phe-Ala-Glu-Ala-Phe-Gly-NH2 (8) 85 
3 Fmoc-d-Val-d-Ala-D-Glu-d-Arg-d-Phe-d-Ala- NH2 (9) 80 
4 Fmoc-d-Val-Ala-Glu-d-Arg-d-Phe-Ala-NH2 (10) 80 
5 Fmoc-Cys-Gly-Arg-Arg-Ala-Cys-Gly-Glu-Phe-Ala-Gly-NH2, disulfide bond (11) 75 
6 Fmoc-Arg-Ala-Glu-Ala-Gly-Ser-Gly-Phe-NH2 (12) 90 
aReaction conditions: peptide (1 equiv) was reacted with PyBrop (20 equiv), DIEA (20 equiv), and a crystal of DMAP in DMF 
followed by cleavage with 0.1 M phosphate buffer (pH 7.5) at 25 °C for 48 h unless otherwise noted.b Yield of N-terminal fragment 
with Fmoc group.c Three fragments were detected in the HPLC trace for cleavage at both Glu residues. . Table adopted from 
Nalbone, J. M.; Lahankar, N.; Buissereth, L.; Raj, M. Org. Lett. 2016, 18, 1186 with permission  
 
                 Subsequently, bioactive peptides: 13, a putative coproporphyrinogen III oxidase fragment, 16, 
and Aβ (10−19), 36  19, a fragment of Alzheimer’s disease associated amyloid-β peptide (entries 1−3, Table 
2.4, and Figure A18-A20, Supplementary Information ) were cleaved successfully with good 79-80% 
conversion to the product. 
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Table 2.4. Glu-Selective Cleavage of Bioactive Peptides 
entry substrate yielda (%) 
1 Fmoc-Met-Gly-His-Gln-Glu-His-Leu-Pro-Tyr- NH2 (13) 79 
2 Fmoc-Leu-Pro-Arg-Leu-Gln-Glu-Ala-Trp-Gln- NH2 (16) 75 
3 Fmoc-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-NH2 (19) 80 
4 Fmoc-Ala-Gly-Leu-Pro-Glu-Lys-Tyr-NH2 (22) 82 
a Yield of N-terminal fragment with Fmoc group. Table adopted from Nalbone, J. M.; Lahankar, N.; Buissereth, L.; Raj, M. Org. 
Lett. 2016, 18, 1186 with permission.  
                Finally, this methodology was evaluated on a bioactive peptide, amyloid A protein fragment 
(Homo sapiens) 22, with a proline residue next to Glu (entry 4, Table 4). The location of proline at a 
neighboring position nearly blocks the cleavage by proteases completely independent of the amino acid 
residue, 27, 28 but remarkably this method cleaved the Pro-Glu bond with 82% conversions to the peptide 
fragments. Interestingly, even though peptides 19 and 22 contained lysine residues with a free side-chain, 
cyclization was observed only at Glu to generate the kinetically favorable five-membered pGlu moiety 
(Figure A20, A21 Supporting Information) further confirming high specificity and broad substrate scope 
of the cleavage strategy.  
2.7 CONCLUSIONS  
             In this study, a site-selective approach for the cleavage of peptides at the N-terminus of Glu under 
mild and metal-free reaction conditions with high specificity was developed. The method was tolerant  
to wide range of unprotected side chains functionalities within the tested peptides unlike some other 
chemical cleavage methods. In addition, as disulfide bonds are stable toward reaction conditions, this 
methodology can be useful for determining the position of disulfide pairing in peptides.  Moreover, the 
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method exhibited broad substrate scope including the cleavage of peptides at proteolytically resistant 
Pro-Glu sites. Similarly, hydrolysis of mutated peptides with unnatural amino acid residues such as D-
amino acids, unsuitable substrates for enzymes, proceeded with ease under the reaction conditions. The 
strategy presents a potential valuable complementary tool for peptide and protein sequencing with a 
broad substrate scope, including cleavage of bioactive peptides and mutated peptides with unnatural 
amino acid residues such as D-amino acids implicated in various diseases. The results of this study have 
provided a foundation for further studies aimed at developing artificial chemical proteases for the 
cleavage of target proteins responsible for various diseases 
2.8 EXPERIMENTAL SECTION  
General.  
         All commercial materials (Aldrich, Fluka, Nova) were used without further purification. All solvents 
were reagent grade or HPLC grade (Fisher).  Anhydrous THF, diethyl ether, CH2Cl2, and DMF were obtained 
from a dry solvent system (passed through column of alumina) and were used without further drying.  All 
reactions were performed under air in round bottom flask. Yields refer to chromatographically pure 
compounds; % yields were obtained by comparison of HPLC peak areas of products and starting material. 
HPLC was used to monitor the reaction progress.   
 Materials. 
          Fmoc-amino acids were obtained from Nova Biochem under (EMD Millipore Corporation) (Billerica, 
Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained from ChemPep Inc 
(Wellington, Florida). N,N,N′,N′-Tetramethyl-O-(1Hbenzotriazol-1-yl)uronium hexafluorophosphate 
(HBTU) was obtained from CreoSalus (Louisville, Kentucky). N, N′-Disuccinimidyl carbonate (DSC) was 
obtained from Nova Biochem, under (EMD Millipore Corporation) (Billerica, Massachusetts). 
Bromotris(pyrrolidino)phosphonium hexafluoro-phosphate (PyBrop) was obtained from Sigma Aldrich (St. 
Louis, Missouri). 4-Dimethylaminopyridine (DMAP): Merck KGaA (Darmstadt, Germany). N, N-
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Dimethylformamide (DMF): Macron Fine Chemicals (Center Valley, Pennsylvania). Dichloroethane (DCE), 
acetonitrile, N, N- Diisopropylethylamine (DIEA), N, N'diisopropylcarbodiimide (DIC), were purchased 
from (EMD Millipore Corporation) (Billerica, Massachusetts). Piperidine was purchased from Alfa Aesar 
(Ward Hill, Massachusetts).  
Trifluoroacetic acid (TFA) was purchased from VWR (100 Matsonford Road Radnor, PA). Diethyl Ether: 
Sigma Aldrich (St. Louis, Missouri). Water was purified using a Millipore MilliQ water purification system.   
 NMR:  
            Proton NMR spectra were recorded on a 600 MHz spectrometer and carbon NMR spectra on a 151 
MHz spectrometer at ambient temperature. All NMR chemical shifts (δ) are referenced in ppm relative 
to residual solvent or internal tetramethylsilane. 1H NMR chemical shifts are referenced to residual 
DMSO-d5 at 2.50 ppm, and 13C NMR chemical shifts are referenced to DMSO-d6 at 39.52 ppm. Carbon 
NMR spectra are proton decoupled. NMR spectral data are reported as chemical shift (multiplicity, 
coupling constants (J), integration). Multiplicity is reported as follows: singlet (s), broad singlet (bs), 
doublet (d), doublet of doubles (dd), doublet of triplet (td), triplet (t) and multiplet (m). Coupling constant 
(J) in Hertz (Hz). 
HPLC  
Semi-Preparative HPLC:   
          Semi-preparative HPLC chromatography (HPLC) was performed on Beckman Coulter equipped with 
System Gold 168 detector and 125P solvent module HPLC with a 10 mm C-18 reversed-phase column. All 
separations involved a mobile phase of 0.1% FA (v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile 
(solvent B). Semi-preparative HPLC method using a linear gradient of 0–80% acetonitrile in 0.1% aqueous 
FA over 30 min at room temperature with a flow rate of 3.0 mL min-1. The eluent was monitored by 
absorbance at 220 nm and 254 nm unless otherwise noted.  
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 Analytical HPLC:   
      Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100 series HPLC equipped with 
a 4.6 x150 mm (5µm) C-18 reversed-phase column. All separations involved a mobile phase of 0.1% FA 
(v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide compositions were 
evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in acetonitrile versus 0.1% FA in 
water. Analytical HPLC method using a linear gradient of 0–80% 0.1% FA (v/v) acetonitrile in 0.1% aqueous 
FA over 30 min at room temperature with a flow rate of 1.0 mL min-1. The eluent was monitored by 
absorbance at 254 nm unless otherwise noted.   
 LCMS:  
        Mass spectrometry was performed using ultra high-performance liquid chromatography-mass 
spectrometry using the Agilent 1100 Series LCMSD VL MS Spectrometer using positive polarity 
electrospray ionization (+ESI). 
 Fmoc Solid-Phase Peptide Synthesis.37 
        Peptides were synthesized manually on a 0.25 mmol scale using a Rink amide resin. The Fmoc–group 
was deprotected using 20% piperidine–DMF for 20 min to obtain a deprotected peptide-resin. Fmoc-
protected amino acids (1.25 mm) were sequentially coupled on the resin using a HBTU (1.25 mmol) and 
DIEA (1.25 mmol) for 2 h at room temperature. Peptides were synthesized using standard protocols.37 The 
peptide was cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic acid:triisopropyl 
silane:water for 2 h. The resin was removed by filtration and the resulting solution was concentrated.  The 
oily residue was triturated with diethyl ether to obtain a white suspension.  The resulting solid was purified 
by HPLC.  
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General Procedure for cyclization of a peptide:  
         To a 5-mL round-bottom flask containing peptide (I) (20 mg, 1 equiv.) in 1 mL dimethylformamide 
(DMF) was added a solution of PyBrop (20 equiv.), DIEA (20 equiv.) and crystal of DMAP in DMF (0.5 mL). 
The mixture was stirred at room temperature for 24 h. The reaction was concentrated under vacuum and 
resulting peptide was dissolved in 1:1 mixture of water and acetonitrile and purified by HPLC. The purified 
fractions were lyophilized to afford cyclized peptide (II) as a white powder; yield: (80 %). 
General procedure for the cleavage of peptides:  
        To a cyclized peptide (2a-j), 1 mL phosphate buffer (pH 7.5) was added. The reaction was stirred at 
25 °C and monitored by analytical HPLC at regular intervals. The reaction mixture was lyophilized, purified 
by HPLC and isolated. HPLC: 0.1% FA (v/v) in water (solvent A): 0.1% FA (v/v) acetonitrile (solvent B); 
gradient 0-80 %, 0.1% FA (v/v) acetonitrile in 25 min, flow rate = 1.0 mL/min, detection wavelength 254 
nm. 
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CHAPTER 3. PEPTIDE STAPLING VIA UREA BRIDGING - CHEMICAL INSIGHTS INTO CYCLIC 
PEPTIDE SYNTHESIS 
3.1. ABSTRACT 
               An efficient synthesis strategy has been developed for peptide stapling onto activated lysine 
residues. In this approach, a two-step one pot reaction featuring activation of the side chain amino group 
of lysine with carbonyl diimidazole followed by urea bond formation with an adjacent side chain amino 
group of a second lysine residue was accomplished without the need of any metal catalyst. This 
methodology was used to synthesize a stapled Axin mimetic analogue, which demonstrated increased 
alpha helicity and improved proteolytic stability upon peptide stapling. Moreover, a bicyclic peptide was 
prepared with this strategy, to further extend the scope of reaction. Finally, this methodology can be 
potentially applied for the production of urea stapled peptides as mild and efficient synergistic catalysts 
for carrying out a range of organic asymmetric transformations like Michael Addition, and C-H 
functionalization reactions with high reactivity and selectivity. 
3.2 GRAPHICAL ABSTRACT 
 
Figure 3.1. General method for the synthesis of urea-bridged cyclic peptides 
3.3. INTRODUCTION 
                Peptide drugs have gained a wide range of applications in treating human malignancies such as 
cancer (Goserelin, a synthetic gonadotropin-releasing hormone analog), multiple sclerosis (Glatiramer 
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acetate, a synthetic peptide with four amino acids), and type 2 diabetes (Exenatide, a synthetic glucagon-
like peptide-1 analog).1  Peptides can provide target specificity, potency and longer resident times for 
more effective duration of action which improves biological efficacy and minimizes side effects.2, 3 
However, short synthetic peptides exhibit poor pharmacokinetic and pharmacodynamics properties 
which limits their translation into the clinic.4 In addition, peptides are susceptible to proteolytic 
degradation1 and they are poorly cell permeable which further restricts their drug-like characteristics.5 
3.3.1 BIOACTIVE CYCLIC PEPTIDES 
            As stapling linear peptides constrains them into cyclic form, the likelihood of the formation of 
intramolecular hydrogen bonds increases, which can decrease interactions with water, thus, increasing 
the potential for membrane permeability by passive diffusion.6  In addition, constrained cyclic peptides 
contain amide bonds  which are more difficult to access by proteases, thereby improving their proteolytic 
resistance. Moreover, the structural stability resulting from cyclization favors biologically active 
conformations of cyclized peptides like Vasopressin and Desmopressin (antidiuretic hormones 
Eptifibatide (an antithrombolytic agent), Oxytocin (hormone related to childbirth and social bonding) 
(Figure 3.2 )7 with target molecules; thus decreasing the entropic cost upon binding to their target.8 For 
the aforementioned reasons, stapling short peptides can greatly improve their pharmacological 
performance. 
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Figure 3.2 Bioactive cyclic peptides 
  3.3.2 SYNTHESIS OF CYCLIC PEPTIDES 
Since the development of stapling techniques by Grubbs9 and Verdine using Ring-Closing 
Metathesis (RCM),10 various stapling methods have been explored in order to off-set some of their 
limitations, including the use of transition metal catalysts, un-natural amino acid residues and harsh 
reaction conditions that may denature peptide structure. In spite of their utility, these methods, including 
the use of cysteine side chains to form disulfide bridges11  and thioether formation (crosslinking with ’- 
dibromo-m-xylene,12 aromatic nucleophilic substitutions with perfluoroaromatic reactants),13 the use of 
functionalized non-natural amino acids and biaryl linkages involving the borylated phenylalanine 
derivatives,14- 17 or azide–alkyne cycloadditions (click chemistry)18  still required metal catalysts, usually 
expensive, long stepwise syntheses and the use of unnatural amino acids. 
                Such limitations can be overcome by new practical and general stapling methods involving 
modifications of naturally occurring residues. These stapling strategies are useful in modifying readily 
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available peptides/proteins.19-21 Chemoselective bioconjugation techniques have been developed to 
modify native residues such as lysine and cysteine in order to link them with reactive and functional groups 
that enable peptide cyclization.22  Lysine is considerably more prevalent than cysteine in naturally 
occurring peptides and proteins, 22 and an abundance of methods to selectively modify primary amines 
makes them desirable reactive targets for functionalization. Building on these facts, different one- 
component side-chain stapling methodologies between lysine and other amino acids, like lactamization,23 
have been employed to generate structurally rigid stapled peptides with improved helicity as well as 
biological activity (Figure 3.2, a). Additionally, by introducing a bifunctional linker between the two lysine 
residues, stapled peptides with different properties can be generated from  linear peptides in the more 
versatile two‐component stapling approach (Figure 3.2, b).24 
 
Figure 3.3. a-One-component stapling methodology. BOP: (benzotriazol-1-yloxy) tris 
(dimethylamino)phosphonium hexafluorophosphate, DIPEA: N, N-diisopropylethylamine.  
b- Two- component stapling methodology. 1. CuAAC- Copper-Catalyzed Azide-Alkyne Cycloaddition 
2. RCM- Ring-closing metathesis 
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 Thus, new synthetic chemical approaches for the selective and straightforward modification of lysine 
are of great importance for stapling methodology. 
3.4. CHAPTER OBJECTIVES 
In this thesis chapter, a biocompatible,  two‐component stapling methodology to modify the ε-
amino group of lysine 51 (pKa values of 10.4 in model compounds)52 with a reactive carbonyl donor leading 
to the  formation of a urea functionality with an adjacent deprotonated lysine is reported. We 
hypothesized that in presence of a base and the electrophilic bifunctional linker carbonylating agent, the 
lysine residue will be activated in an intermolecular SN2 reaction to form intermediate A, which will 
subsequently generate the urea-stapled peptide B by an intramolecular nucleophilic attack by another 
lysine residue (Scheme 3.1). This method will be optimized by exploring the influence of the base and 
carbonylating reagent on the cyclization reaction in model peptides. With optimized conditions in hand, 
a series of bio-active peptides will be subjected to the proposed urea stapling strategy to investigate the 
influence of structure on peptide biological activity. 
Scheme 3.1: Proposed mechanism for the urea stapling reaction 
 
3.5 RESULTS AND DISCUSSION 
3.5.1 PRELIMINARY RESULTS 
             To investigate this one-step, two component synthetic strategy, different carbonylating agents, 
namely, N, N'-disuccinimidyl carbonate (DSC), 1,1'-carbonyldiimidazole (CDI),  and 4-nitrophenyl 
chloroformate (NPCF) were screened for lysine reactivity within  a model  N-terminus acetyl-protected 
hexapeptide Ac-Phe-Arg-Lys-Gly-Lys-Ala-CONH2 in dimethylformamide (DMF) as reaction solvent and 
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N,N-diisopropylethylamine (DIEA) as base (Table 3.1). The desired urea-stapled peptide was observed and 
confirmed by LCMS, HRMS, MS/MS, and NMR spectroscopy which validated H/D exchange of the product 
(Figure 3.4). 
 
H/D Exchange Data: # of exchangeable protons = 788 – 773 – 1 = 14 
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Figure 3.4: H/D exchange, MS, MS/MS, HRMS, NMR of stapled Ac-Phe-Arg-Lys-Gly-Lys-Ala-CONH2     
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       Good conversions (69%) were detected by HPLC conversion with CDI as the active carbonylating 
reagent at 250C, (Table 3.1, entry 3), and was subsequently selected as the reagent of choice for the 
stapling reaction. 
Table 3.1. Reagent screening for the urea stapling reaction.a 
 
 
 
 
 
a Reaction conditions: peptide (1 equiv) was reacted with CDI (3 equiv), DIEA (3 equiv) in DMF at 25°C for 
24h. b Conversion to product was calculated with HPLC by measuring absorbance at 220 nm. 
                 The stapling reactions were conducted for 24 h since the reaction of the model peptide Ac-
FKGAKF with CDI, gave optimum conversion (64%) to the product following a one-day reaction (Table 3.2, 
entry 3) (Figure 3.5) 
Table 3.2. Optimization of conditions for the urea stapling reactiona : Time 
entry time convb (%) 
1 5 13.83 
2 10 26.73 
3 24 63.43 
Reaction conditions:   a peptide (1 equiv) was reacted with CDI (3 equiv), DIEA (3 equiv) in DMF at 25°C for 
24h. b Conversion to product was calculated with HPLC by measuring absorbance at 220 nm. 
entry reagent convb(%) 
1 4-nitrophenyl chloroformate 40 
2 DSC 50 
3 CDI 69 
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Figure 3.5: HPLC trace and MS for stapled Ac-Phe-Lys-Gly-Ala-Lys-Phe- NH2 at 250C after 24 h 
 
                Next, in order to optimize the distance between two lysine residues and reaction temperature, 
a series of peptides with two lysine residues separated by varying amino acids were synthesized, and 
subsequently subjected to the optimized CDI conditions at 250C and 650C. 
Table 3.3 Optimization of reaction conditions for urea stapling a: Distance between lysine residues and 
temperature. 
entry peptide                  position of 
              lysine residues 
equiv of 
CDI 
convb to 
product (%) 
250C 
 
equiv 
of CDI 
convb to   
product (%) 
650C 
 
1 Ac-Phe-Lys-Lys-Phe-NH2c (3) i, i+1 3 0 - - 
2 Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 (1) I, i+2 3 69 - - 
3 Ac-Phe-Lys-Gly-Ala-Lys-Phe- NH2 (2) i, i+3 3 63 - - 
4 Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 (4) i, i+4 3 86 - - 
5 Ac-Arg-Lys-Ala-Leu-Gly-Ala-Lys-Phe-NH2 (5) i, i+5 3 40 -  
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6 Ac-Phe-Lys-Val-Ala-Leu-Gly-Ala-Lys- 
Phe-NH2 (6) 
 
i, i+6 3 0 
 
- - 
7 Ac-Phe-Lys-Gly-Lys-Leu-NH2 (7) I, i+2 3 32 3 63 
8 Ac-Phe-Lys-Phe-Lys-Leu-NH2 (8) I, i+2 3 9 3 74 
9 Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 (1) I, i+2 - - 9.2 94 
10 Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 (4) i, i+4 - - 7 98 
11 
 
 
Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His- 
Val-Gln-Arg-Val-Met-NH2 (9) 
 
i, i+4 - - 6 89 
12 
 
Ac-Thr-Ser-Phe-Lys-Glu-Tyr-Trp-His-Leu-Leu 
-Ser-NH2 (10) 
i, i+4 - - 8 93 
13 Ac- Ala-Lys-Leu-Gly-Phe-Lys-Leu-NH2 (11) i, i+4 - - 7 44 
14 
 
Ac- Ile-Lys-Leu-Gly-Phe-Lys-Leu-NH2 (12) i, i+4  - 7 67 
15 Phe- Lys-Leu-Gly-Ala-Lys-Phe-Glu (13) i, i+4 - - 9 99 
a Reaction conditions: peptide (1 equiv) was reacted with CDI, DIEA in DMF at 25°C for 24 h. bConversion 
to product was calculated with HPLC by measuring absorbance at 220 nm. c Reaction continued for 48 h, 
23.587% intermediate. 
                At 250C, high conversion to the urea stapled peptide was obtained when two lysine residues were 
at i and i+2, i and i+3 and i and i+4 positions with good HPLC conversions ranging from 69% to 86% (Table 
3.3, entries 2-4) (Figure 3.4, 3.5, 3.6).  
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Figure 3.6: HPLC trace and MS for stapled Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 (4) at 250C after 24 h 
Though stapled product was obtained with lysine residues at positions i and i+5, modest HPLC conversion 
to product was observed (40%, Table 3.3, entry 5) (Figure 3.7), while no stapled product was detected 
with lysine residues at i and i+ 6 positions (Table 3.3, entry 6). 
 
Figure 3.7: HPLC trace and MS Ac-Arg-Lys-Ala-Leu-Gly-Ala-Lys-Phe-NH2 (5a) at 250C after 24 h 
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               When the stapling reaction was carried out with 3 equiv of CDI at 650C, it gave better conversion 
to product than for the reaction at 250C (Table 3.3, entries 7 and 8), though, the amount of CDI for 
maximum conversion to product varied from peptide to peptide. (Table 3.3, entries 9 and 10) (Figure A23, 
A31, Supplementary Information).     
               We then proceeded to investigate the selectivity of the stapling reaction toward other residues 
in the peptide chain. Two model peptides, Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-
Met-CONH2 (9) and Ac-Thr-Ser-Phe-Lys-Glu-Tyr-Trp-His-Leu-Leu-Ser-CONH2 (10) that contained all 
nucleophilic residues except for cysteine, it being more nucleophilic than lysine (pKa  around  8.5), 27 were 
designed (Table 3.3, entries 11 and 12 respectively) (Figure 3.8).  
              Both the peptides reacted cleanly without any by-products even with unprotected side chains of 
other amino acids in peptides. Urea stapled product was obtained for both peptides (9a and 10a) with 
high HPLC conversion ranging from 89% to 93%. Thus, the urea stapling methodology is chemoselective 
to the lysine side-chain amino groups in N- terminus Ac- protected peptides in the presence of reactive 
functional groups, namely, alcohols and carboxylic acids in the peptides (Table 3.3, entries 11 and 12). 
(Table 3.3, entries 11 and 12 respectively) (Figure3.8).  
 
 
 
 
 
Figure 3.8: Selectivity of peptide stapling: Stapled peptides Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-
Val-Gln-Arg-Val-Met-NH2 (9a) and Ac-Thr-Ser-Phe-Lys-Glu-Tyr-Trp-His-Leu-Leu-Ser-NH2) (10a) 
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                 We then aimed to explore the steric effect of side-chain functionality of the amino acids adjacent 
to lysine residues on the efficiency of the stapling reaction. There was only 9% HPLC conversion to the 
product for the peptide Ac-Phe-Lys-Phe-Lys-Leu-NH2 (8) with the bulky phenylalanine in between the 
reactive lysine residues, whereas, 32% conversion was observed for the peptide Ac-Phe-Lys-Gly-Lys-Leu-
NH2 (7) at 250C which involved substitution of Phe3 for Gly3 (Table 3.3, entries 8 and 7, respectively) (Figure 
3.9). Thus, the bulky Phe3 residue had an adverse effect on peptide stapling efficiency when compared to 
the sterically unencumbered Gly3 residue.  
 
 Figure 3.9: HPLC traces of stapled Ac-Phe-Lys-Gly-Lys-Leu-NH2 (7a) and Ac-Phe-Lys-Phe-Lys-Leu-NH2 (8a)               
         At 650C, HPLC conversion to product for peptide Ac-Ile-Lys-Leu-Gly-Phe-Lys-Leu-NH2 (12) with bulky  
isoleucine residue placed outside the stapling site was 67% compared to 44% for peptide Ac-Ala-Lys-Leu-
Gly-Phe-Lys-Leu-NH2 (11) which substituted Ile1 for Ala1 (Table 3.3, entries 14 and 13 respectively), while 
peptide Ac-Phe-Lys-Phe-Lys-Leu-NH2 (8) with  bulky  Phe1 inside the stapling site gave 74% HPLC 
conversion to product, as against 63% for  peptide Ac-Phe-Lys-Gly-Lys-Leu-NH2 (7) (Table 3.3, entries 8 
and 7 respectively), indicating that steric bulk did not  affect efficiency of stapling reaction at elevated 
temperature, whether outside or inside the staple to be formed.  
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3.5.2. PROTEOLYTIC STABILITY OF THE STAPLED PEPTIDE  
                The proteolytic stability of the stapled peptide belonging to an Axin mimic was compared to its 
linear analogue (Figure 3.10). Axin analogue Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-
Met-NH2 (9) (25 μM)  widely reported in various peptide stapling papers28 and its urea stapled analogue 
(9a) were subjected to  in vitro trypsin29 digestion in 1 M phosphate buffer (0.5 ng/μL, 250C, pH 7.3) and 
monitored for degradation by  LC/ MS.  Degradation of the linear peptide was completed in 30 min 
producing four detectable fragments, confirmed by MS (Figure 3.10b, 3.11a). In contrast, stapled peptide, 
while intact after 30 min, showed only one fragment containing the urea moiety, 
, which did not degrade even after 90 min (9v) incubation, 
confirmed by MS. Thus, the urea stapled Axin peptide exhibited increased structural stability towards 
proteolysis. (Figure 3.9b,3.10b). 
 
Figure 3.10 a) Expected cleavage sites for linear peptide and stapled peptide upon exposure to trypsin. 
b) Actual fragments obtained for linear peptide and stapled peptide after exposure to trypsin. 
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Figure 3.11a: MS traces of linear Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 (9) 
and its four (9i-iv) fragments after digestion with trypsin  
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9a 
  
9V 
 
 
Figure 3.11b: MS trace of stapled Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 (a) 
and fragment (9v) after digestion with trypsin. 
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3.5.3 SECONDARY STRUCTURE ANALYSIS OF THE STAPLED PEPTIDE 
               The Axin mimetic Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 (9) and its 
urea stapled analogue (9a) were next explored to detect their secondary structures (if any) using Circular 
Dichroism (CD) spectroscopy30 (Figure 3.12). When dissolved in TFE/water, the urea stapled peptide 
clearly showed the α-helical signature with an observed minima at 208 nm and 222 nm and a maxima at 
190 nm (Figure 31.2a). The comparison of the helical propensity indicated that the urea stapled peptide 
had a higher tendency (50%) to adopt α-helical character in 1:9 v/v TFE: water while the unstapled linear 
peptide exhibited a weaker (21%) helical structure (Figure 3.12b).  
 
Figure 3.12: Helicity of linear and urea stapled peptide: CD spectra recorded for the peptide (5 μM) with 
different amounts of TFE in phosphate buffer (pH 7.3). Urea stapled peptide indicated a high tendency to 
adopt α-helical character. 
3.5.4 SYNTHESIS OF A BICYCLIC PEPTIDE 
In order to illustrate the application of the urea-stapling methodology, a bicyclic peptide was 
synthesized as a new class of bioactive bicyclic compounds.31 In this synthesis strategy, the first ring was 
constructed by protecting the acid side chain of glutamic acid. The free N-terminus amino group of the 
peptide was used for on-resin head-to-tail cyclization with the C-terminus carboxylic acid group of the 
model peptide NH2-Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-COOH (13) (Scheme 3.2). Overnight reaction in the 
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presence of HOAT/DIC (Scheme 3.2) generated the first ring (13a), confirmed by HRMS and NMR (Figure 
3.13). The second cyclization reaction was carried out by the urea stapling methodology of two internal 
lysine residues (Scheme 3.2, 13b) and the product was confirmed by MS and NMR (Figure 3.14).  From the 
ion mobility mass spectrometry (IMS) data (Figure 3.15), the bicyclic peptide was shown to exist as two 
conformational diastereomers, 13b-1 (retention time tR 11.2min) and 13b-2 (retention time tR 12.4min). 
However, the conformer 13b-1 (92%) was found to dominate conformer 13b-2 (6%) (Figure 3.16) Thus, an 
appropriate choice of the protection scheme allowed for the synthesis of structurally diverse bicyclic 
peptides by our urea stapling strategy.  
Scheme3.2:  Synthesis of a bicyclic compound: stapling strategy 
. 
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HRMS data- Monocycle Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-CONH2: [C46H69N11O9+2H]2+: m/z [M+2/2]+  
460.768  (calc.M+2/2]+ 460.77), [ M+H]+m/z 920.52 (calcd [M+H]+ =920.53) 
 
Figure 3.13: HRMS and 1H NMR   for Monocyclic peptide Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-CONH2 (13a) 
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MS Bicycle Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
 
Figure 3.14: MS and 1H NMR of Bicycle Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
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Extracted Mass Spectra: Bicyclic Peptide Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Ion Mobility Resolved MS/MS (Overlay) (A) 328 Å2 and (B) 339 Å2 Conformations for 
bicyclic Peptide Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
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Figure 3.16: HPLC trace of two conformational diastereomers, 13b-1 and 13b-2 of the bicyclic Peptide 
Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
 
3.6 CONCLUSIONS 
In conclusion, a urea-based strategy for stapling and cyclizing peptides has been developed in this 
thesis chapter. The methodology is chemoselective to lysine residues and utilizes an electrophilic 
carbonylating reagent, CDI, to generate the urea stapled peptide. This mild, one-step, two-component 
method works without any metal catalyst. A structural study of the urea stapled peptide displayed 
increased α-helicity, and also improved proteolytic stability. Moreover, this stapling strategy was 
successfully applied to generate bicyclic peptides as a new type of scaffold for peptide-based drug design. 
Finally, the unique feature of this methodology is the generation of a urea moiety that is capable of 
forming H-bonds and thus can play an important role in catalysis. Future studies will be used to address 
the application of urea stapled peptides as efficient catalysts for carrying out a range of organic 
asymmetric transformations such as the Michael Addition, and C-H functionalization reactions. 
  72 
3.7. EXPERIMENTAL SECTION  
General:  
               All commercial materials (Aldrich, Fluka, Nova) were used without further purification. All 
solvents were reagent grade or HPLC grade (Fisher).  CH2Cl2 and DMF were obtained from a dry solvent 
system (passed through column of alumina) and were used without further drying. All reactions were 
performed under air in a round bottom flask. Yields refer to chromatographically pure compounds;  
% conversions were obtained by comparison of HPLC peak areas of products and starting material. HPLC 
was used to monitor reaction progress. 
Materials:  
           Fmoc-amino acids were obtained from Nova Biochem under (EMD Millipore Corporation) (Billerica, 
Massachusetts) and CreoSalus (Louisville, Kentucky). Rink amide resin was obtained from ChemPep Inc 
(Wellington, Florida). N,N,N′,N′-Tetramethyl-O(1H-benzotriazol-uronium hexafluorophosphate (HBTU) 
was obtained from CreoSalus (Louisville, Kentucky). N, N′-Disuccinimidyl carbonate (DSC) was obtained 
from Nova Biochem, under (EMD Millipore Corporation) (Billerica, Massachusetts). 4-
Dimethylaminopyridine (DMAP): Merck KGaA (Darmstadt, Germany). N, N-Dimethylformamide (DMF): 
Macron Fine Chemicals (Center Valley, Pennsylvania). Acetonitrile, N, N-Diisopropylethylamine (DIEA), N, 
N'-diisopropylcarbodiimide (DIC), were purchased from (EMD Millipore Corporation)(Billerica, 
Massachusetts). Piperidine was purchased from Alfa Aesar (Ward Hill, Massachusetts). 1,1'-
Carbonyldiimidazole (CDI) was purchased from Nova Biochem (Calbiochem-Novabiochem corporation, La 
Jolla, California) Trifluoroacetic acid (TFA) was purchased from VWR 100 Matsonford Road Radnor, PA. 
Water was purified using a Millipore MilliQ water purification system.   
Analytical HPLC: 
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                Analytical HPLC chromatography (HPLC) was performed on an Agilent 1100 series HPLC equipped 
with a 4.6 x150 mm (5µm) C-18 reversed-phase column. All separations involved mobile phase of 0.1% FA 
(v/v) in water (solvent A) and 0.1% FA (v/v) in acetonitrile (solvent B). Peptide compositions were 
evaluated by analytical reverse phase HPLC using a gradient of 0.1% FA in acetonitrile versus 0.1% FA in 
water. Analytical HPLC method using a linear gradient of 0–80% 0.1% FA (v/v) acetonitrile in 0.1% aqueous 
FA, unless otherwise noted, over 30 min at room temperature with a flow rate of 1.0 mL min-1. The peptide 
absorbance was monitored at 220 nm (peptide bond) unless otherwise noted. 
LC-MS:  
             Mass spectrometry was performed on an Agilent 1100 Series HPLC with MSD VL mass 
spectrometer using positive polarity electrospray ionization (+ESI). 
LC-HRMS:  
               Analysis was done at Merck facilities at Rahway, NJ by Ryan Cohen. High resolution MS data were 
acquired using an Agilent 1290 UHPLC with a 6520 Q-ToF mass spectrometer under positive polarity 
electrospray ionization (+ESI) with capillary and fragmentor voltages set to 3.5 kV and 175 V, respectively. 
The instrument was calibrated prior to data acquisition using Agilent’s reference standard solution, which 
provided accurate masses within 5 ppm. A reversed phase, linear gradient separation was performed at a 
flow rate of 1.0 mL min-1 on a C18 column (Waters Acquity UPHLC peptide BEH C18, 1.7 µm particle size, 
50 mm x 2.1 mm I.D.) thermostatted at 45°C and gradient from 95% solvent A (0.1% formic acid in water) 
to 99% solvent B (0.1% formic acid in acetonitrile) in 4 minutes, followed by 1 minute re-equilibration. 
MS/MS:  
               Analysis was done was done at Merck facilities at Rahway, NJ by Ryan Cohen. Tandem MS 
analyses were performed either on an Agilent 1260 HPLC coupled with a 6530 Q-ToF or on an Agilent 1290 
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HPLC coupled with a 6520 Q-ToF mass spectrometer. Both mass spectrometers were operated under 
electrospray ionization in positive polarity (+ESI). Reverse phase C18 gradient separation conditions were 
used (mobile phase A = 0.1% formic acid in water and mobile phase B = 0.1% formic acid in acetonitrile). 
Spectra were acquired in profile mode with collision energies ranging from 25-90 V and nitrogen (N2) as 
collision gas. 
NMR:  
              NMR was done by Ryan Cohen at Merck facilities at Rayway, NJ. NMR spectra were recorded on a 
Bruker AVANCE III HD 600 MHz spectrometer equipped with a 5-mm HCN cryoprobe at 600 and 151 MHz 
for proton and carbon, respectively, spectrometer at ambient temperature.  An approximately 1 mg 
sample was dissolved in DMSO-d6 solvent containing 0.05% v/v TMS for chemical shift referencing.  1H, 
13C, gCOSY, TOCSY (80 ms mixing time), multiplicity-edited gHSQC, gHMBC, and ROESY (200 ms spin lock) 
experiments were performed. NMR spectra were processed using MNova (ver. 11.0.4). 
               All NMR chemical shifts are referenced in ppm relative to residual solvent or internal 
tetramethylsilane. 1H NMR chemical shifts referenced to residual DMSO-d5 at 2.50 ppm, and 13C NMR 
chemical shifts referenced to DMSO-d6 at 39.52ppm. Carbon NMR spectra are proton decoupled. NMR 
spectral data are reported as chemical shift (multiplicity, coupling constants (J), integration). Multiplicity 
is reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of doubles (dd), doublet of triplet 
(td), triplet (t) and multiplet (m). Coupling constant (J) in Hertz (Hz). 
 
General Procedure for Fmoc Solid-Phase Peptide Synthesis32: 
               Peptides were synthesized manually on a 0.25 mmol scale using Rink amide resin. Fmoc–group 
was deprotected using 20% piperidine–DMF to obtain a deprotected peptide-resin (2x 20 min). Fmoc-
  75 
protected amino acids (1.25 mmol) were sequentially coupled on the resin using a HBTU (1.25 mmol) and 
DIEA (1.25 mmol) for 2 h at room temperature. Peptides were synthesized using standard protocols. The 
peptide was cleaved from the resin using a cocktail of 95:2.5:2.5, trifluoroacetic acid (TFA): 
triisopropylsilane (TIPS): water (H2O) for 2 h. The resin was removed by filtration and the resulting solution 
was concentrated under vacuum. The resulting solid was dissolved in ACN-water solvent system, analyzed 
and purified by RP HPLC. 
General Procedure for Stapling Reaction:   
              To a 5-mL round-bottom flask containing peptide (1 equiv.) in 200 μL dimethylformamide (DMF) 
was added a solution of CDI (3-9.2 equiv.) and DIEA (3-9.2 equiv.) in DMF. The mixture was stirred at 
250C/650C for 24 h.  The reaction mixture was concentrated under vacuum and resulting peptide was 
dissolved in mixture of water and acetonitrile and purified by RP HPLC. The purified fractions were 
lyophilized to afford stapled peptide as a white powder. % conversion was obtained by comparison of 
HPLC peak areas of products and starting material. HPLC was used to monitor reaction progress. 
Macrocyclization of Linear Peptide, Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu, on Solid Support:  
              To peptide, Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu, containing O-allyl protected glutamic acid on solid 
support (50 mg, 0.69 mmol/g) was added a 3 mL solution of 20 mg Pd (PPh3)4 and 72 µL phenylsilane in 
DCM. This solution was incubated on a shaker at room temperature for 40 minutes. The resin was washed 
with DCM (3 X 2 min). The above reaction was repeated, and then the resin was washed with DCM (3 X 2 
min), MeOH (3 X 2 min), and DMF (3 X 2 min). The palladium catalyst was removed from the resin by 
washing with DIEA in DMF (2% v/v) (2 X 2 min) and then with DMF (2 X 2 min). Next, the peptide was 
treated with 20% piperdine in DMF to remove the Fmoc protection. Macrocyclization was achieved by 
exposing the resin to DIC, HOAt, and a catalytic amount of DMAP in DMF on a shaker for 15 h. The solution 
was drained, and the resin was washed with DMF. To confirm complete macrocyclization, the Kaiser test32 
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was performed, which showed yellow bead coloration indicating absence of free amino groups. The 
peptide was then cleaved from the resin by 2 hours incubation with a solution of TFA:TIPS:water 
(95/2.5/2.5, v/v/v). Resin was removed by filtration, and the resulting solution was evaporated. The 
peptide was purified by reversed-phase semi-preparative chromatography. 
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CHAPTER 4: CONTRIBUTIONS TO KNOWLEDGE AND FUTURE DIRECTIONS 
4.1 CONTRIBUTIONS TO KNOWLEDGE MADE IN THIS THESIS  
         In this thesis, side chain modified polypeptides have been developed to affect both conformational 
as well as functional properties. The effect of cyclic conformational constraint on the   peptide backbone 
and the side chain geometry were explored as chemical tools for improving peptide structure–activity 
relationships. 
4.1.1 PYROGLUTAMATE - A CYCLIC BACKBONE INTERMEDIATE FOR SELECTIVE CHEMICAL CLEAVAGE 
          OF PEPTIDE BONDS 
           The second chapter of the thesis describes a site-selective cleavage at glutamic acid of unreactive 
peptide bonds in native peptides as well as in peptidomimetics (Figure 4.1).  
 
 Figure 4.1: Graphical abstract for Glutamic Acid Selective Chemical Cleavage of Peptide Bond.  
            To develop this method, we optimized the reaction conditions for activation of the peptide 
backbone amide bond at glutamic acid by the formation of a reactive pyroglutamyl (pGlu) imide 
intermediate. Next, the reactive pGlu imide moiety was subjected to hydrolysis, resulting in cleavage of 
the scissile peptide bond at the N-terminus of the modified glutamic acid residue. The method exhibited 
broad substrate scope. When we explored different substrates to study the effect of steric bulk of 
neighboring amino acid residues on the efficiency of chemical cleavage, there was no significant effect. 
  80 
However, substrates with bulky residues such as isoleucine required longer incubation times for the 
cleavage reaction to proceed to completion. Moreover, the cleavage reaction proceeded without any by-
products, demonstrating selectivity of the reaction. Cleavage of mutated peptides with unnatural amino 
acid residues such as D-amino acids, unsuitable substrates for enzymes, proceeded with ease under the 
reaction conditions. Moreover, disulfide bonds were stable toward the reaction conditions in contrast to 
other chemical reagents such as the use of cyanogen bromide.  Importantly, this methodology was 
successful in cleaving peptide bonds next to proline, a site inaccessible to proteases. Finally, the scope of 
the methodology was successfully extended to different bioactive peptides such as a fragment of putative 
coproporphyrinogen III oxidase, amyloid-β peptide; and amyloid A protein.  
              The significance of this chemical cleavage strategy lies in the fact that it presents a potential 
valuable complementary tool for peptide and protein sequencing (Figure 4.2). 
                                              Primary Structure determination  
 
Steps  Technique 
I. Determination of amino acid sequence in a  protein 
 
Complete hydrolysis of a protein Pronase enzyme 
Separation and estimation of amino acids Chromatography 
II. Protein  degradation  in smaller fragments 
 
Liberation and determination of number of polypeptide 
chains 
Urea, Dansyl chloride 
Cleavage of polypeptides into fragments Enzymatic, Glutamic acid 
selective 
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Figure 4.2: Peptide sequencing with glutamic acid selective chemical cleavage 
 The results of this study have provided a foundation for further studies aimed at developing artificial 
chemical proteases for the cleavage of target proteins responsible for various diseases (Figure 4.2B). The 
importance of this study was acknowledged by a publication in Organic Letters.  
4.1.2 PEPTIDE STAPLING VIA UREA BRIDGING-CHEMICAL INSIGHTS INTO CYCLIC PEPTIDE SYNTHESIS 
In the third chapter of this thesis, a urea-based methodology between two lysine residues for 
stapling and cyclizing peptides has been reported. First, we explored a suitable base and a carbonylating 
reagent to deprotonate and activate the lysine side chain. In our optimized conditions, 1,1'-
carbonyldiimidazole (CDI) and N, N-diisopropylethylamine (DIEA) were selected as the reagents of 
choice. This activation step led to formation of a urea functionality with an adjacent lysine residue 
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(Figure 4 .3). 
 
Figure 4.3: Mechanism for the urea stapling reaction 
         High conversion to the urea stapled peptide was obtained when two lysine residues were at i and 
i+2, i and i+3 and i and i+4 positions. When the steric effect of amino acids adjacent to lysine residues was 
investigated, we observed that bulky residues like phenylalanine in between the lysine residues had an 
adverse effect on the efficacy of the stapling reaction. The methodology was chemoselective to the lysine 
side-chain amino groups in N- terminus Ac- protected peptides in presence of reactive functional groups, 
namely, alcohols and carboxylic acids. Moreover, the urea stapled peptide exhibited increased structural 
stability towards proteolysis as well as higher tendency to adopt α-helical structure. The major advantage 
of this stapling strategy is that it can successfully generate bicyclic peptides. The latter was accomplished 
in the case of model peptide NH2-Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu--COOH.  
The unique feature of this methodology is the generation of a urea moiety that is capable of 
forming H-bonds and thus can play an important role in catalysis. Future studies will be used to address 
the application of urea stapled peptides as efficient organocatalysts for carrying out a range of organic 
asymmetric transformations like Michael Additions, and C-H functionalization reactions (Figure 4.4).  
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Figure 4.4: Urea stapled peptides as efficient organocatalysts: a) Michael Addition b) Design of 
Organic Catalyst c) Mechanistic Pathway of Peptide Catalysis  
4.1.3 REFERENCES:     
1. Nalbone, J.M.; Lahankar, N.; Buissereth, L.; Raj, M. Org. Lett. 2016, 18, 1186. 
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• Glutamic Acid Selective Chemical Cleavage of Peptide Bonds – Nalbone, J. M.; Lahankar, N.; 
Buissereth, L.; Raj, M. Org Lett. 2016, 18, 1186. 
• Amino-Acid-Catalyzed Direct Aldol Bioconjugation – Howard T. S.; Cohen R. D.; Nwajiobi O.; 
Muneeswaran Z. P.; Sim, Y. E.; Lahankar N. N.; Johannes T.-H. Y.; Raj, M. Org. Lett. 2018, 20, 5344.  
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Figure A1: HPLC trace, 1H /13C HSQC NMR, 1H /13C HMBC NMR,1H /1H ROSEY NMR for linear and 
HPLC trace for cyclized Fmoc-Gly-Glu. Product peak is labeled. 
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Figure A2: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A3: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A4: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A5: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A6: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A7: HPLC traces  of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A8: HPLC traces   of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A9: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A10: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A11: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A12: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A13: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A14: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A15: HPLC traces  of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A16: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A17: HPLC traces  of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A18: HPLC traces  of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A19: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A20: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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Figure A21: HPLC traces of cyclized starting material and the crude reaction mixture after incubation in 
buffer solution. Product peak is labeled. 
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CHAPTER 3 
 
Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Linear Peptide (1) - LCMS: m/z 747.6 (calcd [M+H]+ = 747.893), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 6.1 min. (HPLC method of 0–80% 0.1% FA) 
Figure A22 : HPLC trace and MS of  Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Linear Peptide 
 
 
Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled peptide (1a) at 250C- LCMS: m/z 773.5 (calcd [M+H]+ = 773.88 ), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: Starting material 4.902min, Product 7.848 min 
(HPLC method of 0–80% 0.1% FA).Reactant  31.30%,  Product 68.70%. 
  131 
 
Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled peptide (1a) at 650C (9.2 equiv CDI) - LCMS: m/z 773.5 (calcd 
[M+H]+ = 773.88 ), Purity: >95% (HPLC analysis at 220 nm). Retention time: Starting material 5.6i5 min. 
Product 9.422 min (HPLC method of 0–80% 0.1% FA). Reactant  5.788%,  Product 94.212%.
 
Figure A23: HPLC trace of Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide at 250C and 650C. The product 
peak is labeled. 
 
13C NMR for Lys-Lys stapled Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 (1a). 
13C NMR (151 MHz, DMSO-d6)  (ppm) 174, 171.6, 171.3, 171, 170.7, 169.3, 168.6, 157.9, 157, 137.9, 129, 
127.9, 126.153.9, 52.2, 51.9, 51.8, 47.9, 42.3, 40.1, 38.8, 38.7, 37.3, 32.2, 31.7, 29, 28.8, 28.7, 24.8, 22.4, 
22.3, 21.6, 18.2. 
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1H/1H COSY NMR for Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide (1a) 
 
1H /1H TOCSY NMR for Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide (1a) 
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1H /13C HSQC NMR for Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide (1a) 
 
1H /13C HMBC NMR for Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide (1a) 
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 1H /1H ROSEY NMR for Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide (1a) 
 
Figure A24 : 13C NMR, 1H/1H COSY NMR, 1H /1H TOCSY NMR, 1H /13C HSQC NMR, 1H /13C HMBC NMR,  
1H /1H ROSEY for Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 Stapled Peptide 
  135 
 
Ac- Phe-Lys-Gly-Ala-Lys-Phe-NH2 (2) - LCMS: m/z 738.9 (calcd [M+H]+ = 738.88), Purity: >95% (HPLC 
analysis at 220 nm). Retention time: 9.9 min. (HPLC method of 0–80% 0.1% FA) 
           
Figure A25 : HPLC trace and MS of Ac- Phe-Lys-Gly-Ala-Lys-Phe NH2 Linear Peptide 
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Ac- Phe-Lys-Gly-Ala-Lys-Phe-NH2 Stapled peptide (2a) after 5 h: LCM-: m/z 764.88 (calcd [M+H]+ = 
764.87), Purity: >95% (HPLC analysis at 220 nm). Retention time: reactant 8.662 min., Product 11.273 min. 
(HPLC method of 0–80% 0.1% FA).Reactant 86.167%. Product 13.833%. 
 
 
Ac-Phe-Lys-Gly-Ala-Lys-Phe-NH2 peptide Stapled (2a) after 10 h: LCM-: m/z 764.88 (calcd [M+H]+ = 
764.87), Purity: >95% (HPLC analysis at 220 nm). Retention time: reactant 8.642 min., Product 11.087 min. 
(HPLC method of 0–80% 0.1% FA). Reactant 73.270%. Product 26.730%. 
 
Figure A26: HPLC trace of Ac-Phe-Lys-Gly-Ala-Lys-Phe-NH2 Stapled after 5h and 10 h. The product peak is 
labeled. 
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1H NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a). 
1H NMR chemical shifts referenced to residual DMSO-d6 at 2.50 ppm and 13C NMR   chemical shifts 
referenced to DMSO-d6 at 39.52 ppm.  
 1H NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a 
1H NMR (600 MHz, DMSO-d6)   (ppm)  8.30 (m, 1H), 8.30 (m, 1H), 7.98 (d, J = 8.4Hz, 1H), 7.97(d, J = 8.5 
Hz, 1H), 7.91 (d, J = 6.5 Hz, 1H),  7.65 (d, J = 8.3 Hz, 1H), 7.33(s, 1H), 7.17 (m, 2H), 7.17 (m, 2H), 7.17 (m, 
2H), 7.13 (m, 2H), 7.11 (m, 1H), 7.11 (m, 1H), 7.02 (s, 1H), 5.76 (t, J = 5.2 Hz, 1H), 5.29 (t, J = 4.8 Hz, 1H), 
4.45 (m, 1H), 4.34 (m, 1H), 4.19 (m, 1H), 4.18 (m, 1H),  4.12 (m, 1H), 3.93 ( dd, J = 16.4, 6.1 Hz, 1H), 3.39 
(dd, J=16.1, 5.8 Hz, 1H), 3.02 (m, 1H), 2.99 (m, 1H), 2.94 (dd, J = 14.2, 5.4 Hz, 1H), 2.90 (m, 1H), 2.88 (m, 
1H), 2.87 (m, 1H),  2.74 (dd, J=14.1, 8.0 Hz, 1H), 2.65 (m, 1H),  1.67 (s, 1H),  1.55 (m, 1H),  1.55 (m, 1H),  
1.39 (m, 1H),  1.38 (m, 1H), 1.32 (m, 1H), 1.30 (m, 1H), 1.28 (m, 1H), 1.23 (m, 1H), 1.17 (m, 2H), 1.18 (m, 
1H), 1.13 (d, J=7.2 Hz, 3H), 1.11 (m, 1H).  
 
 
 
 
 
13C NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a). 
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13C NMR (151 MHz, DMSO-d6)  (ppm) 172.2, 171.3, 171.2, 170.7, 169.4, 169, 157.8, 137.9, 129, 127.8, 
126, 53.6, 51.9, 51.9, 48.1, 41.6, 38.2, 37.8, 37.3, 31.1, 30.5, 28.5, 27.8, 22.3, 22, 21, 17.5. 
 
 
1H/1H COSY for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a) 
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1H /1H TOCSY NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a). 
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1H /13C HSQC NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a). 
 
1H /13C HMBC NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe- NH2 Stapled Peptide (2a) 
 
1H /1H ROSEY NMR for Ac- Phe-Lys-Gly-Ala-Lys-Phe-NH2 Stapled Peptide (2a) 
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Figure A27 : 1H NMR, 13C NMR, 1H/1H COSY NMR, 1H /1H TOCSY NMR, 1H /13C HSQC NMR, 1H /13C HMBC 
NMR, 1H /1H ROSEY NMR for Stapled Peptide Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 
 
Ac-Phe-Lys-Lys-Phe-NH2 Linear Peptide (3): LCMS- m/z 609.9 (calcd [M+H]+ = 609.752), Purity: >95% (HPLC 
analysis  
at 220 nm). 
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Figure A28- MS of Ac-Phe-Lys-Lys-Phe-NH2  Linear Peptide 
 
 
Expected Ac-Phe-Lys-Lys-Phe-NH2 Stapled Peptide (3a): (calcd [M+H]+ = 635.646) was not obtained, but 
intermediate (3b)  was obtained.   
Intermediate (3b)-LCMS: m/z 703.1 (calcd [M+H]+ =703.823), Purity: >95% (HPLC analysis at 220 nm). 
Retention time: Starting material 8.303 min intermediate - 12.582 min (HPLC method of 0–80% 0.1% FA) 
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Intermedia23.587%
 
 
 
Figure A29: HPLC trace and MS of Ac-Phe-Lys-Lys-Phe-NH2  Intermediate. The product peak is labeled. 
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Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Linear Peptide (4): LCMS- m/z 876.5 (calcd [M+H]+ =877.05), Purity: 
>95% (HPLC analysis at 220 nm). Retention time: 10.7 min. (HPLC method of 0–80% 0.1% FA) 
 
Figure A30: HPLC trace and MS of Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Linear Peptide 
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Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled peptide (4a) (CDI 7 equiv) at 650C -LCMS: m/z 903.04 (calcd 
[M+H]+ = 902.6), Purity: >95% (HPLC analysis at 220 nm). Retention time: Staring material 10.141 min. 
Product 13.697 min. (HPLC method of 0–80% 0.1% FA). Reactant 2.042%, Product 97.958% 
 
 
HRMS data: Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) [C41H67N13O10+H]+:  calc. m/z 
902.5207, obs. m/z 902.5208 
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MS of Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
 
 
 
 
 
 
 
H/D Exchange Experiment: Fmoc--Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
 
 
Observed # of exchangeable protons = 1099 – 1082 – 1 = 16. Expected # of exchangeable protons = 16   
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Figure A31: HPLC trace (at 650C), MS, HRMS, H/D Exchange experiment of Ac-Arg-Lys-Leu-Gly-Ala-Lys-
Tyr-NH2 Stapled Peptide. Product peak is labled. 
 
1H NMR Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
1H NMR chemical shifts referenced to residual DMSO-d6 at 2.50 ppm and 13C NMR   chemical shifts 
referenced to DMSO-d6 at 39.52 ppm.  
1H NMR (600 MHz, DMSO-d6) 1H NMR   (ppm)  9.22( br s, 1H), 8.28 (t, J =5.8 Hz, 1H), 8.22 (d, J =7.8 Hz, 
1H), 8.12 (d, J =7.8 Hz, 1H), 8.02 (d, J = 6.5 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.81( t, J = 5.2 Hz, 1H,) 7.61 ( d, 
J Hz = 8.1,1H), 7.26 (s, 1H), 7.05 (s, 1H), 6.97 (d, J = 8.4 Hz, 2H), 6.62 (d, J = 8.4 Hz, 2H,) 5.80 (t,  J= 5.9 Hz, 
1H),  5.77 (t, J = 6.1 Hz, 1H), 4.40-4.34 (m, 1H), 4.33-4.28 (m, 1H),  4.30-4.26 ( m, 1H), 4.30-4.24 (m, 1H),
 4.26-4.20 (m, 1H), 4.04-3.99 (m, 1H), 3.73 (dd, J = 16.7, 5.5 Hz, 1H), 3.69 (dd, J =16.8, 5.7 Hz, 1H), 
3.10-3.00 (m, 2H), 3.06-3.02 (m, 1H), 3.02-2.96 (m, 1H), 2.96-2.90 (m, 1), 2.96-2.90 (m, 1H), 2.88 (dd, 
J=14.2, 5.1 Hz, 1H),  2.71 (dd, J = 14.2, 8.5 Hz, 1H), 1.85 (s, 3H), 1.71-1.65 (m, 1H), 1.67-1.59 (m, 1H), 1.61-
1.55 (m, 1H),  1.57-1.47 (m, 1H), 1.56-1.45 (m,2H), 1.53-1.46 (m,  1H), 1.51-1.43 (m, 2H), 1.50-1.43 (m, 
2H), 1.36-1.28 (m, 1H),  1.36-1.27 (m, 2H), 1.30-1.20 (m, 2H),  1.27-1.22 (m, 1H), 1.26-1.16 (m, 2H), 1.18 
(d, J = 6.8, 3H Hz), 0.87 (d, J = 6.5 Hz, 3H), 0.81 (d, J = 6.4 Hz, 3H). 
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 13C NMR Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a).  
13C NMR (151 MHz, DMSO-d6)  (ppm) 172.7, 172.3, 172, 171.4, 171.3, 171.2, 169.2, 168, 158.5, 157, 
155.7, 130, 127.6, 114.7, 53.7,  53.2, 52.2, 51.7, 51.1, 47.8, 41.9, 40.4, 40.1, 38.9, 38, 36.6, 31.5, 30.7, 
29.5, 29.4, 29.1, 24.7, 24, 22.9, 22.4, 22.2, 21.4, 18. 
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 1H/1H COSY for NMR Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
 
1H /1H TOCSY NMR for NMR Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
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1H /13C HSQC NMR for Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
 
1H /13C HMBC NMR for Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
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1H /1H ROSEY NMR for Ac-Arg-Lys-Leu-Gly-Ala-Lys-Tyr-NH2 Stapled Peptide (4a) 
 
Figure A32 : 1H NMR, 13C NMR, 1H/1H COSY NMR, 1H /1H TOCSY NMR, 1H /13C HSQC NMR, 1H /13C HMBC 
NMR, 1H /1H ROSEY for Stapled Peptide Ac-Phe-Arg-Lys-Gly-Lys-Ala-NH2 
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Ac-Arg-Lys-Ala-Leu-Gly-Ala-Lys-Phe-NH2 Linear Peptide (5): LCMS- m/z 930.5 (calcd [M+H]+ =931.1), 
[(M+2/)2] += 465.8 (calcd [(M+2/)2]+= 466.5)  Purity: >95% (HPLC analysis at 220 nm). Retention time: 5.4 
min. (HPLC method of 0–80% 0.1% FA). 
 
Figure A33: HPLC and  MS of linear peptide Ac-Arg-Lys-Ala-Leu-Gly-Ala-Lys-Phe-NH2 Linear Peptide. 
Product peak is labled. 
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Ac-Phe-Lys-Gly-Lys-Leu-NH2 Linear Peptide (7):- LCMS: m/z 632.9 (calcd [M+H]+ =633.787), Purity: >95% 
(HPLC analysis at 220 nm).  
 
Figure A34: MS of Ac-Phe-Lys-Gly-Lys-Leu-NH2 Linear Peptide. Product peak is labled. 
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Ac-Phe-Lys-Gly-Lys-Leu-NH2 Stapled Peptide (7a) at 650C -LCMS: m/z 659(calcd [M+H]+ =659.781), 
Purity: >95% (HPLC analysis at 220 nm). Retention time:  Reactant 7.984 min., Product 10.915 min (HPLC 
method of 0–80% 0.1% FA) Reactant 36.529%, Product 63.471%. 
 
 
Figure A35: HPLC trace and MS Ac-Phe-Lys-Gly-Lys-Leu-NH2 Stapled Peptide (8a) at 650C. The product 
peak is labeled. 
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Ac-Phe-Lys-Phe-Lys-Leu-NH2 Linear (8):- LCMS- m/z 723.9 (calcd [M+H]+ = 723.911 ), Purity: >95% (HPLC 
analysis at 220 nm). Retention time:  min. (HPLC method of 0–80% 0.1% FA). 
 
 
Figure A36: HPLC trace and MS of Ac-Phe-Lys-Phe-Lys-Leu-NH2 Linear Peptide (8). The product peak is 
labeled. 
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Ac-Phe-Lys-Phe-Lys-Leu-NH2 Stapled Peptide (8a) at 650C: LCMS- m/z 749.8 (calcd [M+H]+ = 749.805), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: Reactant 10.796 min. Product 13.604 min. 
Reactant 26.033%, Product 73.967% (HPLC method of 0–80% 0.1% FA). 
 
 
 
 
Figure A37: HPLC trace and MS of Ac-Phe-Lys-Phe-Lys-Leu-NH2 Stapled Peptide (8a) at 650C. Product 
peak is labled. 
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Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Linear Peptide (9): LCMS: 
[(M+2/)2] += 939.1 (calcd [(M+2/)2]+= 939.58), [(M+3/)3] += 626.67 (calcd [(M+3/)3] += 626.5),Purity: > 
95%. (HPLC analysis at 220 nm). Retention time: Reactant 11.305 min. (HPLC method of 0–60% 0.1% FA). 
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Figure A38: HPLC trace and MS of Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 
Linear Peptide (9) 
 
Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Stapled Peptide (9a)-LCMS: 
[(M+2/)2] += 952.58 (calcd [(M+2/)2]+ = 952.58), Purity: > 95% (HPLC analysis at 220 nm). Retention time: 
Reactant 11.647 min, Product 14.189 min. (HPLC method of 0–60% 0.1% FA). Reactant 10.667%, Product 
89.333%. 
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Figure A39: HPLC trace and MS of Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 
Stapled Peptide(9a). Product peak is labeled. 
 
Ac-Thr-Ser-Phe-Lys-Glu-Tyr-Trp-His-Leu-Leu-Ser-NH2Linear Peptide(10): LCMS:[M+H]+=1443.658. (calcd 
[M+H]+) =1442.6. [M+2/2] += 722 (calcd [M+2/2]+) =722.329), Purity: > 95% (HPLC analysis at 220 nm). 
Retention time: 8.183 min. (HPLC method of 0–60% 0.1% FA). 
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Figure A40: HPLC trace and MS of Ac-Thr-Ser-Phe-Lys-Glu-Tyr-Trp-His-Leu-Leu-Ser-NH2 (10) Linear 
Peptide 
Stapled peptide (10a):-LCMS: m/z 1470.9 (calcd [M+H]+ =1469.652), Purity: >95% (HPLC analysis at 220 
nm). Retention time: Starting material 8.253 min. Product 18.861, 19.761 min (HPLC method of 0–60% 
0.1% FA). Reactant 6.629%, Product 93.371%. 
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Figure A41: HPLC and MS of Ac-Thr-Ser-Phe-Lys-Glu-Tyr-Trp-His-Leu-Leu-Ser-NH2 Stapled Peptide (10) . 
Product peak is labaled. 
 
Ac- Ala-Lys-Leu-Gly-Phe-Lys-Leu-NH2 (11): Linear-LCMS: m/z 816.9 (calcd [M+H]+ =817.025), Purity: >95% 
(HPLC analysis at 220 nm). Retention time: 7.826 min. (HPLC method of 0–80% 0.1% FA)  
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Figure A42: HPLC trace and MS of Ac- Ala-Lys-Leu-Gly-Phe-Lys-Leu-NH2 Linear Peptide (11)  
Stapled peptide (11a)-LCMS: m/z 844.8 (calcd [M+H]+ =844.01), Purity: >95% (HPLC analysis at 220 nm). 
Retention time:  Reactant 7.891 min. Product 9.364 min, 9.692 min. (HPLC method of 0–80% 0.1% FA). 
Reactant 56.632%, Product 43.639%.  
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Figure A43: HPLC trace and MS of Ac- Ala-Lys-Leu-Gly-Phe-Lys-Leu-NH2 (11a) Stapled Peptide. Product 
peak is labeled 
 
Ac- Ile-Lys-Leu-Gly-Phe-Lys-Leu-NH2 Linear Peptide (12): -LCMS: m/z 859.06 (calcd [M+H]+ =860.10), 
Purity: >95% (HPLC analysis at 220 nm). Retention time: 11.170 min. (HPLC method of 0–80% 0.1% FA) 
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Figure A44: HPLC trace  and MS of Ac- Ile-Lys-Leu-Gly-Phe-Lys-Leu-NH2 Linear Peptide (12). Product peak 
is labeled. 
Stapled Peptide (12a)-LCMS: m/z 885.8 (calcd [M+H]+ = 886.09), Purity: >95% (HPLC analysis at 220 nm). 
Retention time- Reactant 12.650 min: Product 14.022 min, 14.215 min. (HPLC method of 0–80% 0.1% FA). 
Reactant 32.916%, Product 67.084%. 
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Figure A45 : HPLC trace and MS of Ac- Ile-Lys-Leu-Gly-Phe-Lys-Leu-NH2 (12) Stapled Peptide. Product 
peak is labled. 
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 Stability study of Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Linear 
Peptide(9): -LCMS: [(M+2/)2] += 939.1 (calcd [(M+2/)2]+= 939.58), [(M+3/)3] += 626.67 (calcd [(M+3/)3] += 
626.5),Purity:> 95%. (HPLC analysis at 220 nm). Retention time: Reactant 11.305 min. (HPLC method of 0–
60% 0.1% FA). 
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Figure A46A -1: Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Linear Peptide (9): 0 
min 
 
 
Figure A46 A-2: Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Linear Peptide(9):  
Fragmentation at 30 min: Fragments (9i), (9ii), (9iii), (9iv). 
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Figure A46 A-3: Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Linear Peptide(9):  
Fragmentation after 90 min: Fragments (9i), (9ii), (9iii), (9iv). 
 
 
Figure A46: Stability Study: Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Linear 
Peptide (9): 
Fragmentation after 90 min: Fragments (9i), (9ii), (9iii), (9iv). 
Fragment Ac-Glu-Asn-Pro-Glu-Lys-OH (9i) - LCMS: m/z  658.3 (calcd [M+H]+ = 657.676), Purity: >95% 
(HPLC analysis at 220 nm). Retention time- 5.703 min (HPLC method of 0–60% 0.1% FA). 
Fragment Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 (9ii) - LCMS: m/z  1008.8 (calcd [M+H]+ = 
1008.186), [M+2/2] += 504.0 (calcd [M+2/2]+) =504.593),  Purity: >95% (HPLC analysis at 220 nm). 
Retention time- 6.648 min (HPLC method of 0–60% 0.1% FA).  
 Fragment Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-OH (9iii ) - LCMS:  [(M+2/)2] +=824.5 
(calcd [(M+2/)2]+= 824.424), [(M+3/)3] += 549.7 (calcd [(M+3/)3] += 549.949),Purity:> 95%. (HPLC analysis 
at 220 nm). Retention time: Reactant 9.831 min. (HPLC method of 0–60% 0.1% FA).  
Fragment Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-OH (9iv) - LCMS:  calculated M+2/2= 564.129 LCMS:  
[(M+2/) 2] +=564.1(calcd (M+2/) 2]+= 564.129. Purity:> 95%. (HPLC analysis at 220 nm). Retention time: 
10.622 min. (HPLC method of 0–60% 0.1% FA). 
Figure A46 A: The stability of the Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 
linear (9). 
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Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Stapled Peptide (9a) -LCMS: 
[(M+2/)2] += 952.58 (calcd [(M+2/)2]+ = 952.58), Purity: > 95% (HPLC analysis at 220 nm). Retention time: 
Reactant 11.666 min. (HPLC method of 0–80% 0.1% FA). 
Fragmentation at 0 min. 
 
 
Figure A46 B -1: Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 Stapled Peptide   
(9b): 
Fragmentation at 30 min: (9a) and fragment (9v). 
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Figure A46 B -2:  Fragmentation at 30 min: (9a) and fragment (9v). 
 
Figure A46 B -3:  Fragmentation at 90 min: fragment ((9v). 
Fragment  stapled Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-OH (9v).- LCMS:  [(M+2/)2] +=577.3 (calcd 
[(M+2/)2]+= 577. 126), [(M+3/)3] += 385.6 (calcd [(M+3/)3] += 385.083),Purity:> 95%. (HPLC analysis at 220 
nm). Retention time: 10.548 min. (HPLC method of 0–60% 0.1% FA).  
Figure A46 B : The stability of the stapled peptide. 
Figure A46 : The stability study of Ac-Glu-Asn-Pro-Glu-Lys-Ile-Leu-Asp-Lys-His-Val-Gln-Arg-Val-Met-NH2 
Stapled Peptide compared to its Linear Analogue. 
  171 
 
 
Figure A47 A: MS of Fmoc-Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-(O-allyl)-CONH2 
 LCMS: m/z 1201.4 (calcd[M+H]+=1201.43),  Purity:>95% 
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Figure A47 B: MS of Fmoc-Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-CONH2  
 LCMS: m/z 1162.2 (calcd [M+H]+ = 1161.36), [(M+2/)2] + = 580.7(calcd [(M+2/)2]+= 581.1) Purity: >95% 
Monocyclic peptide Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-CONH2- LCMS: m/z 920.5 (calcd [M+H]+ =921.10), 
[(M+2/)2] += 459.8(calcd [(M+2/)2]+= 461.05) Purity: >95%. (HPLC analysis at 220 nm). Retention time: 
Reactant 9.32 min. (HPLC method of 0–80% 0.1% FA). 
(  
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Figure A48 –HPLC trace and MS of  Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
13C NMR Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
13C NMR (151 MHz, DMSO-d6)  (ppm) 172.9, 172.6, 172.4, 172.2, 172.1, 171.6, 171, 170.6, 169.1, 137.9, 
137.4, 129.2, 129, 128, 127.9, 126.2, 126.2, 54.8, 54.1, 53.7, 52.5, 52.5, 52, 49.1, 42.1, 39.4, 38.5, 38.5, 
37.3, 36.7, 32.6, 31.6, 30.3, 29, 27, 26.9, 24, 22.6, 22.2, 21.8, 21.7, 17.      
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1H/1H COSY NMR Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
 
1H /1H TOCSY NMR Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
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1H /13C HSQC NMR Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
 
1H /13C HMBC NMR Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
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1H /1H ROSEY NMR Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a). 
  
 
Figure A49 : 13C NMR, 1H/1H COSY NMR, 1H /1H TOCSY NMR, 1H /13C HSQC NMR, 1H /13C HMBC NMR,  
1H /1H ROSEY for Monocyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a).  
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Ion Mobility Resolved MS/MS 
 
 
  
Ion Mobility Resolved MS/MS(A) 328 Å2 and (B) 339 Å2 Conformations 
LCMS: m/z 946.7 (calcd [M+H]+ = 947), (M+23) += 968.8 (calcd [(M+23]+= 968.98), (M+39) += 984(calcd 
[(M+39]+)= 985,Purity: >95%.  (HPLC analysis at 220 nm). Retention time: Reactant 8.822 min, Product 
11.177min, 12.374min (HPLC method of 0–80% 0.1% FA). Reactant 0.946%, Product 13b-1  92.491%, 13b-
2- 6.563% 
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Figure A50: Ion Mobility Resolved MS/MS for two Conformations and HPLC  trace of  Bicyclic Phe-Lys-
Leu-Gly-Ala-Lys-Phe-Glu-CONH2  
13C NMR Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b).  
13C NMR (151 MHz, DMSO-d6) δ (ppm)  173.2, 172.9, 172.4, 171.8, 171.6, 171.4, 171, 170.8, 168.7, 158.7, 
138.2, 137.9, 129.3, 129.3, 128.2,  128.2, 126.4, 126.3, 54.9, 54, 52.6, 52.4, 52.2, 51.9, 49, 42.4,  39.5, 39.2, 
38.4, 36.6, 36.1, 32.3, 32.1, 31.1, 28.6, 28.6, 28.2, 24.2, 22.8, 22, 21.6, 20.7, 16.2 
 
1H/1H COSY NMR Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b)  
  179 
 
1H /1H TOCSY NMR Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
 
1H /13C HSQC NMR Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
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1H /13C HMBC NMR Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
 
1H /1H ROSEY NMR Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13b). 
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Figure A51 : 13C NMR, 1H/1H COSY NMR, 1H /1H TOCSY NMR, 1H /13C HSQC NMR, 1H /13C HMBC NMR,  
1H /1H ROSEY for Bicyclic Phe-Lys-Leu-Gly-Ala-Lys-Phe-Glu-NH2 (13a).  
